# A ANNUAL REVIEWS

# Annual Review of Physiology IP<sub>3</sub> Receptor Plasticity Underlying Diverse Functions

# Kozo Hamada and Katsuhiko Mikoshiba

Laboratory of Cell Calcium Signaling, Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, Shanghai, 201210, China; email: hamada@shanghaitech.edu.cn, mikosiba@shanghaitech.edu.cn

Annu. Rev. Physiol. 2020. 82:151-76

First published as a Review in Advance on November 15, 2019

The Annual Review of Physiology is online at physiol.annualreviews.org

https://doi.org/10.1146/annurev-physiol-021119-034433

Copyright © 2020 by Annual Reviews. All rights reserved

# ANNUAL CONNECT


- www.annualreviews.org
- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

# **Keywords**

inositol 1,4,5-trisphosphate receptor, Ca<sup>2+</sup> channel, gating mechanism, allosteric regulation, inositol 1,4,5-trisphosphate, endoplasmic reticulum

#### Abstract

In the body, extracellular stimuli produce inositol 1,4,5-trisphosphate (IP<sub>3</sub>), an intracellular chemical signal that binds to the IP<sub>3</sub> receptor (IP<sub>3</sub>R) to release calcium ions (Ca<sup>2+</sup>) from the endoplasmic reticulum. In the past 40 years, the wide-ranging functions mediated by IP<sub>3</sub>R and its genetic defects causing a variety of disorders have been unveiled. Recent cryo-electron microscopy and X-ray crystallography have resolved IP<sub>3</sub>R structures and begun to integrate with concurrent functional studies, which can explicate IP<sub>3</sub>-dependent opening of Ca<sup>2+</sup>-conducting gates placed ~90 Å away from IP<sub>3</sub>-binding sites and its regulation by Ca<sup>2+</sup>. This review highlights recent research progress on the IP<sub>3</sub>R structure and function. We also propose how protein plasticity within IP<sub>3</sub>R, which involves allosteric gating and assembly transformations accompanied by rapid and chronic structural changes, would enable it to regulate diverse functions at cellular microdomains in pathophysiological states.



#### Figure 1

IP<sub>3</sub>R functions at cellular microdomains. (*a*) In an early study of mutant mice showing motor defects,  $P_{400}$  proteins lacking in Purkinje neuron deficient mice were identified as the IP<sub>3</sub>R (1, 184). Panel adapted with permission from Reference 184. Copyright 1985, S. Karger, AG. (*b*) Morphology of Purkinje neuron dendritic spines in control mice (*top*) and adult mice (*bottom*) lacking IP<sub>3</sub>R1. Panel adapted from Reference 15 under the terms of the Creative Commons Attribution 4.0 International License, **http:// creativecommons.org/licenses/by/4.0**. (*c*) IP<sub>3</sub> is liberated by G protein–coupled receptors (GPCRs), B cell receptors (BCRs), T cell receptors (TCRs), receptors for brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), intercellular adhesion molecules (ICAMs), and epidermal growth factor (EGF) (185–188). IP<sub>3</sub> specifically binds to IP<sub>3</sub>R and opens the Ca<sup>2+</sup> channel. IP<sub>3</sub>R-mediated Ca<sup>2+</sup> release from Ca<sup>2+</sup> stores, including the endoplasmic reticulum (ER) and acidic stores, should occur in various microdomains near the organelle, including mitochondria (Mit), plasma membrane (PM), Golgi, peroxisomes, endosomes, vacuoles, and autophagosomes. The ER contacts Mit at the mitochondria-associated membrane (MAM). Ca<sup>2+</sup> activates gene expression via the nuclear factor of activated T cells (NFAT).

### DISCOVERY OF P<sub>400</sub>/IP<sub>3</sub>R FROM THE BRAIN

In the 1970s, mutant mice with abnormal behaviors were studied, and a large membrane protein called  $P_{400}$ , which is highly abundant in cerebella of normal mice, was almost absent in Purkinje neurons of mutant mice showing motor defects (**Figure 1***a*) (1, 2). The mutant mice had poorly arborized dendrites in Purkinje neurons, while reduced  $P_{400}$  expression resulted in a loss of calcium ion ( $Ca^{2+}$ ) spikes (3), suggesting a correlation of  $P_{400}$  with  $Ca^{2+}$  signaling. The  $P_{400}$  protein was purified (4) and its cDNA was isolated (5). Results showed that the  $P_{400}$  protein is an inositol 1,4,5-trisphosphate receptor (IP<sub>3</sub>R) that releases  $Ca^{2+}$  from the endoplasmic reticulum (ER) in response to inositol 1,4,5-trisphosphate (IP<sub>3</sub>) (6–8). Importantly, because the IP<sub>3</sub>R channel cannot open without  $Ca^{2+}$ , the coincidence of IP<sub>3</sub> and  $Ca^{2+}$  is critical for channel activation (9, 10). To determine the physiological roles of IP<sub>3</sub>R, knockout mice lacking IP<sub>3</sub>R isoforms (IP<sub>3</sub>R1, IP<sub>3</sub>R2, or IP<sub>3</sub>R3) were generated. Severe cerebellar ataxia (11), impaired long-term depression (12), and abnormal dendrites of Purkinje neurons (13) were found in mice lacking IP<sub>3</sub>R1.

Recently generated knockout mice lacking  $IP_3R1$  in the cerebellum and brainstem exhibited the same abnormal behaviors as the  $IP_3R1$  knockout mice (14); however, conditional knockout mice specifically lacking  $IP_3R1$  in Purkinje neurons showed only severe cerebellar ataxia (15). Interestingly, increased spine density and length (**Figure 1***b*) were observed even in adult mice, indicating the critical role of  $IP_3R1$  in spine maintenance of Purkinje neurons in adults (15). The

**IP**<sub>3</sub>**R:** inositol 1,4,5-trisphosphate receptor

**ER:** endoplasmic reticulum

IP<sub>3</sub>R1-mediated regulation of spine morphology was elucidated by IP<sub>3</sub>R-dependent activation of protein kinase C and consequent calmodulin (CaM)-dependent protein kinase II $\beta$  (CaMKII $\beta$ ) phosphorylation, which modulates F-actin bundling to maintain spine structures (16). The gene expression of IP<sub>3</sub>R is related to brain plasticity, and disrupted-in-schizophrenia 1, a susceptibility gene for major psychiatric disorders including schizophrenia, regulates the transport of mRNA encoding IP<sub>3</sub>R1 for synaptic plasticity (17).

In addition to IP<sub>3</sub>R1, knockout mice lacking IP<sub>3</sub>R2 showed impairments of astrocytic Ca<sup>2+</sup> surge and neuronal plasticity by transcranial direct current stimulation, which enhances memory and cognition in humans (18). A number of prominent studies indicate that IP<sub>3</sub>R2 was the major isoform in astrocytes because a large part of calcium signaling is attenuated in IP<sub>3</sub>R2 knockout mice (19, 20). However, this has been debunked by recent studies. Ca<sup>2+</sup> imaging of hippocampal slices revealed that IP<sub>3</sub>R2 and IP<sub>3</sub>R3 were functional in astrocytes and also suggested the presence of functional IP<sub>3</sub>R1 in astrocytes (21). A study using a highly sensitive Ca<sup>2+</sup> indicator clarified Ca<sup>2+</sup> release in cortical and hippocampal astrocytes of IP<sub>3</sub>R2 knockout mice (22). These data shed light not only on IP<sub>3</sub>R2 but also IP<sub>3</sub>R1 and IP<sub>3</sub>R3 that are involved in astrocytic functions.

In the past 40 years, numerous studies have clarified the diverse functions of  $IP_3R$  in living systems, ranging from unicellular organisms to our bodily organs, including the brain; however, how to achieve these diverse functions remains a mystery. Here, we review recent advances in researching the cellular microdomains and protein structures of  $IP_3R$  and discuss how to approach a possible linkage between the diverse functions of  $IP_3R$  and their structural dynamics that we refer to as  $IP_3R$  plasticity.

# **DIVERSE FUNCTIONS OF IP3R AT MICRODOMAINS**

IP<sub>3</sub>R is abundant in the smooth ER and is localized at lower levels in rough ER (23), the Golgi (24), the nucleus (25–27), and the plasma membrane (PM) (28, 29) (**Figure 1***c*). Nuclear IP<sub>3</sub>R plays an important role in gene transcription (30, 31) and is expressed in nuclear calcium stores to mediate nuclear signaling and cause nuclear translocation of protein kinase C (30, 31). Apoptosis induces mixed clusters of IP<sub>3</sub>R1 in the nucleus (32), and IP<sub>3</sub>R1 gene expression in hippocampal CA1 is decreased by neonatal anoxia, which triggers translocation of IP<sub>3</sub>R1 to the nucleus and neuronal cell death (33). In addition to the nucleus, reports show that IP<sub>3</sub>R can locate at the PM of neurons (28), lymphocytes (34), platelets (35), and hepatocytes (36). The studies using chicken B cells lacking endogenous IP<sub>3</sub>R have clarified Ca<sup>2+</sup> influxes via a limited population of the PM-IP<sub>3</sub>R (37, 38). IP<sub>3</sub>R is also located within acid Ca<sup>2+</sup> stores (39–41), which can control autophagy in *Trypanosoma brucei* (42).

The IP<sub>3</sub>R protein also operates at membrane contact sites between the ER and other organelles (**Figure 1***c*). For example, membrane contact sites between the ER and mitochondria, so called mitochondria-associated membranes (MAMs), facilitate transport of  $Ca^{2+}$  from the ER to mitochondria (43, 44). The voltage-dependent anion channel on the outer mitochondrial membrane binds to the IP<sub>3</sub>R via the molecular chaperone glucose-regulated protein 75, and the protein complex links the ER to mitochondria and facilitates  $Ca^{2+}$  transport (45). The mammalian TOR complex 2 interacts with the complex at the MAM (46), and it is proposed that autophagosomes could be formed at the MAM (47, 48). An interaction between the ER protein Bap31 and the mitochondrial fission protein Fission 1 homolog should regulate the induction of apoptosis (49).  $Ca^{2+}$  transport at the MAM has Janus-faced roles and cancer cells require IP<sub>3</sub>R-mediated  $Ca^{2+}$  transfer from the ER to mitochondria for survival, while normal cells induce autophagy for survival by impaired  $Ca^{2+}$  transfer (50). The IP<sub>3</sub>R-binding protein released with IP<sub>3</sub> (IRBIT) is involved in MAM function and structure because the IRBIT knockout reduced staurosporine-induced

# PM:

plasma membrane

MAM: mitochondriaassociated membrane

**IRBIT:** IP<sub>3</sub>R-binding protein released with IP<sub>3</sub>

# EM: electron microscopy

**IBC:** IP<sub>3</sub>-binding core

**SD:** suppressor domain

apoptosis and mitochondrial  $Ca^{2+}$ . In particular, the phosphorylated form of IRBIT (P-IRBIT) likely regulates MAM structure and function (51). IP<sub>3</sub>R also associates with the sigma-1 receptor (Sig-1R), an integral ER membrane protein that regulates IP<sub>3</sub>R at the MAM (52). Recently, choline produced by phospholipase D was found to be an endogenous agonist of Sig-1R to potentiate  $Ca^{2+}$  signals evoked by IP<sub>3</sub>R as an intracellular messenger (53).


The ER frequently contacts the PM in neurons (54, 55) and non-neuronal cells (56, 57). Electron cryotomography (cryo-ET) imaging revealed that the ER-PM contact is mediated by extended synaptotagmins in addition to stromal interaction molecule 1 (55). The ER-PM contact is also mediated by ER-resident Sec22 and PM syntaxins (54). The ER forms ER-PM junctions in pancreatic acinar cells (56), and IP<sub>3</sub>R-containing ER-PM junctions accumulate at the leading edge of focal adhesions during cell migration (57). In fibroblasts, interleukin (IL)-1 promoted colocalization of protein tyrosine phosphatase  $\alpha$  (PTP $\alpha$ ) and focal adhesion kinase (FAK) with the ER and increased association of IP<sub>3</sub>R1 with PTP $\alpha$  and FAK at focal adhesions near the PM (58).

In the brain, ER-ER contacts are frequently observed in the cell body and dendrites of Purkinje neurons, and electron microscopy (EM) clarified that the stacked ER is enriched with  $IP_3R$  (23, 59-61). In the stacked ER, two apposed IP<sub>3</sub>Rs bridge between ER layers (61), and this finding is supported by formation of a stacked ER in cells upon overexpression of full-length  $IP_3R$  but not by deletion mutants (62). The brief anoxia of oxygen-deprivation (3 min) is enough to cause formation of a stacked ER in Purkinje neurons (63), which is reversible by reoxygenation (64). While structural data has accumulated, physiological roles of the stacked ER remain unknown. A putative Bcl-2 inhibitor apogossypol induced ER aggregation, caused by reorganization of the ER membrane in various cell lines and even in the fission yeast (65). Apogossypol-stimulated  $Ca^{2+}$  efflux from the ER is partially mediated by IP<sub>3</sub>R because 2-aminoethoxydiphenyl borate, an inhibitor of IP<sub>3</sub>R and the transient receptor potential (TRP) channel, completely blocked the apogossypol-dependent ER aggregation (66), but the mechanism is not clear. Membrane contact sites between the lysosomes and the ER/sarcoplasmic reticulum would regulate  $Ca^{2+}$  release by lysosomes, but the mechanism is not clearly understood (67). The ER also makes contacts with the other organelles such as phagosomes, peroxisomes, endosomes, and vacuoles (68, 69), but the functional roles of the IP<sub>3</sub>R in these contact sites remain unknown.

# **IP3R STRUCTURE AND FUNCTIONAL DOMAINS**

The genes for three IP<sub>3</sub>R subtypes (IP<sub>3</sub>R1–3) were cloned from various vertebrates (5, 70–73). All vertebrate IP<sub>3</sub>R genes encode a large cytosolic domain and a small Ca<sup>2+</sup> channel domain (**Figure 2***a*). Approximately 55% of amino acid residues in the full-length mouse IP<sub>3</sub>R1 are conserved among the three isoforms, particularly in the critical regions responsible for IP<sub>3</sub>R function. Molecular cloning uncovered alternative splicing sites (SI–SIII) (**Figure 2***a*) in rodents (73–75) and humans (76), giving rise to phenotypic diversity of IP<sub>3</sub>R channels, and RNA processing at these splicing sites is controlled during development and differentiation (74, 75, 77).

The cytosolic domain contains key functional domains, including an IP<sub>3</sub>-binding core (IBC) (78), an adjacent amino (N)-terminal suppressor domain (SD) that reduces the affinity of IP<sub>3</sub> binding (79), and large regulatory/coupling domains containing various allosteric sites for phosphorylation, binding proteins, and regulators including Ca<sup>2+</sup> (**Figure 2***a*). IBC is the minimum region required for specific IP<sub>3</sub> binding and is mapped within residues 226–578 of mouse type-1 IP<sub>3</sub>R (IP<sub>3</sub>R1). The crystal structure of IBC (residues 224–604) in a complex with IP<sub>3</sub> was determined at a resolution of 2.2 Å (80). Early electron microscopy (EM) studies predicted that the IBC could be located at the top surface distant from the channel domain (81, 82). The most recent cryo-EM studies clarified the precise location of IBC (**Figure 2***b*) (83–85). Eleven amino



(Caption appears on following page)

#### Figure 2 (Figure appears on preceding page)

IP<sub>3</sub>R structures and allosteric gating. (a) Schematic primary structures of IP<sub>3</sub>R. The upper panel shows functional domains and critical residues in IP<sub>3</sub>R1 (78, 79, 116), and proteolytic fragments of IP<sub>3</sub>R1 are drawn below (6). Each domain is depicted in a different color: suppressor domain (SD) in yellow (amino acid residues 1–225); IP<sub>3</sub>-binding core (IBC) in red (residues 226–604); the large regulation/coupling domain in tan, including α-helical domain 1 (HD1; residues 605-1,009), α-helical domain 2 (HD2; residues 1,026-1,493),  $\alpha$ -helical domain 3 (HD3; residues 1,593–2,217), and channel domain in pale blue (residues 2,218–2,749). The bottom panel shows structural domains of IP<sub>3</sub>R (84), and IP<sub>3</sub>/Ca<sup>2+</sup>-binding sites are indicated by arrows. Alternative splicing sites are indicated by SI, SII, and SIII. (b) The 3D structure of IP<sub>3</sub>R1. The left panel shows a cryo-EM map (EMD9244) with a model (6MU2) of structural domains. The right model delineates functional domains and critical residues. (c) Conformational changes induced by IP<sub>3</sub>. Comparison of an X-ray crystal structure resolved in the absence (colored) or presence (gray) of IP<sub>3</sub>. Two X-ray crystal structures of IP<sub>3</sub>R2217 were superimposed by fitting the N-terminal  $\beta$ -rich domain (residues 7–430) (112). (d)  $Ca^{2+}$ -dependent conformational changes demonstrated by IP<sub>3</sub>-bound and IP<sub>3</sub>/Ca<sup>2+</sup>-bound cryo-EM structures of hIP<sub>3</sub>R3 (85). (e) Conformational ensemble in IP<sub>3</sub>-bound states. Structures of Apo-state, IP3 class 1, IP3 class 3, IP3 class 4, IP3 class 5, and IP3 class 2. The relocated HD2/ARM2 domain of each subunit (*blue*) is indicated by an arrow (85). (f) Allosteric gating and its regulation. Schematic model in the absence of  $Ca^{2+}$  in which IP<sub>3</sub> can bind, resulting in an ensemble of distinct conformations, but it cannot open the channel gate (top). In contrast, IP<sub>3</sub> can open the channel gate in the presence of low  $Ca^{2+}$ that can bind to a  $Ca^{2+}$  sensor, probably the JD- $Ca^{2+}$  site near E2100 and the leaflet (*middle*). In case of high  $Ca^{2+}$ , IP<sub>3</sub> cannot open the channel gate because  $Ca^{2+}$  binds to the inhibitory  $Ca^{2+}$  site, presumably the CD-Ca<sup>2+</sup> site, which could induce large conformational changes and subunit dissociations (bottom).

acid residues, including K508/R511 in the IBC domain, are responsible for the correct recognition of IP<sub>3</sub>; all of these residues except Gly268 are conserved in the other IP<sub>3</sub>R isoforms (72, 86). Molecular dynamics simulation of IBC suggests that the conserved Arg241-Glu439 salt bridge determines flexibility of the IBC domain in the ligand-free state (87).

The SD functions as a suppressor for IP<sub>3</sub> binding, and the deletion of SD results in a significant enhancement of IP<sub>3</sub> binding (78, 79). The atomic resolution structure of the SD of mouse IP<sub>3</sub>R1 was determined using X-ray crystallography at a resolution of 1.8 Å (88). The location of the SD was unexpectedly different from some predictions of the direct coupling of the SD to the channel domain (**Figure 2b**). Mutagenesis indicated that the residue Y167/W168 in the SD is critical for IP<sub>3</sub>-induced Ca<sup>2+</sup> release, but not for IP<sub>3</sub>-binding (89). Thus, the Y167/W168-containing hot-spot loop (HS-loop) was proposed to be located near the channel. However, all structures determined by recent cryo-EM studies have demonstrated that the HS-loop is far from the channel domain and is located close to the interfaces between subunits (**Figure 2b**). Therefore, the HS-loop should be considered necessary for subunit interaction rather than direct coupling to the channel.

Because the SD inhibits IP<sub>3</sub> binding within the IBC domain, the SD was considered to bind and mask the IP<sub>3</sub>-binding pocket directly. The N-terminal 604 residues containing the SD and IBC domain showed ~50 nM of dissociation constant for IP<sub>3</sub> (IP<sub>3</sub>R1), ~14 nM for IP<sub>3</sub>R2, and ~160 nM for IP<sub>3</sub>R3 (90). These values are close to those of the full-length IP<sub>3</sub>Rs (73), whereas the IBCs of all subtypes show identical affinities (~2 nM) for IP<sub>3</sub>, suggesting that the subtype-specific IP<sub>3</sub>-binding affinities should be due to each SD. Analyses of site-directed mutagenesis on the SD of mouse IP<sub>3</sub>R1 showed that seven conserved amino acid residues are critical for the suppression of IP<sub>3</sub> binding (88) and that eleven IP<sub>3</sub>R3 specific loops were critical for the IP<sub>3</sub>R3-specific IP<sub>3</sub>binding affinity (90). Therefore, direct association of these residues to the IP<sub>3</sub>-binding pocket was proposed. The first X-ray crystal structures (3.8 Å) showing IP<sub>3</sub>-dependent conformational changes were solved using the N-terminal domain of rat IP<sub>3</sub>R1 (residues 7–602 and 322–336 were removed) and then recombinant protein (residues 1–604) with mutated cysteine residues. In both X-ray crystal structures, unexpectedly the SD did not mask the IP<sub>3</sub>-binding pocket itself (91, 92), suggesting that these critical residues for suppression of IP<sub>3</sub> binding may fix IBC conformation. All-atom molecular dynamics simulations of the N-terminal domains, including the SD and IBC, demonstrated the characteristic twist motion of the SD and revealed the correlated dynamics of IBC with IP<sub>3</sub> binding (93). These reports could elucidate the mechanism of how the SD affects the conformational changes of IBC. However, the role of the HS-loop, including Y167/W168, still remains unknown.  $Ca^{2+}$  imaging using IP<sub>3</sub>R-null HeLa cells generated by genome editing revealed that mutations in a genetic brain disorder, spinocerebellar ataxia 29 (SCA29), identified within or near the IBC completely abolished channel activity (94). Interestingly, a major part of these mutations showed impaired IP<sub>3</sub> binding to IP<sub>3</sub>R1, whereas the T579I and N587D mutations disrupted channel activity without affecting IP<sub>3</sub> binding, suggesting that these two residues should be involved in allosteric regulation.

Although Bikonta IP<sub>3</sub>R does not have completely conserved critical residues in the IP<sub>3</sub>-binding site, and the endogenous IP<sub>3</sub>R of *Trypanosoma cruzi* is localized in acid Ca<sup>2+</sup> stores but not in the ER (40), they exhibit IP<sub>3</sub>-binding activity in *Paramecium* (95) and *T. cruzi* (96). The IP<sub>3</sub>-evoked Ca<sup>2+</sup> release activities in *Paramecium* tetraurelia (95), *T. brucei* (41), and *T. cruzi* (96) have been confirmed. *T. cruzi* is the pathogenic parasite of Chagas disease, whereas *T. brucei* causes African trypanosomiasis or sleeping sickness. Therefore, they should be drug targets because IP<sub>3</sub>R controls cell death events in parasites (97).

# **CONFORMATIONAL CHANGES IN IP<sub>3</sub>R**

To date, the basic mechanism by which local conformational changes in the IBC can open the  $Ca^{2+}$  channel in the IP<sub>3</sub>R remains elusive because of difficulties associated with studying allosteric mechanisms over the long distance between IP<sub>3</sub>-binding sites and the  $Ca^{2+}$  channel. Among the known ligand-gated ion channels whose atomic structures have been solved by X-ray crystallog-raphy or cryo-EM, such as the nicotinic acetylcholine receptor (98), NMDA (99), AMPA (100), GABA<sub>A</sub> (101), 5-HT<sub>3</sub> (102), P<sub>2</sub>X (103), and ryanodine receptor (RyR) (104), the distance from ligand-binding sites to the  $Ca^{2+}$  channel in IP<sub>3</sub>R is the longest.

Early EM studies on tetrameric IP<sub>3</sub>R structure were performed by negative staining of purified IP<sub>3</sub>R (81, 105–107), and cryo-EM studies were published from several groups (82, 108, 109); however, their published maps showed different structures, and the discrepancies have been discussed in review papers (110, 111). Thereafter, the IP<sub>3</sub> receptor structure at a 17-Å resolution was published, followed by the recent revolution of cryo-EM technology that uncovered the structure of IP<sub>3</sub>R at a 3- to 5-Å resolution (83–85). These high-resolution maps of IP<sub>3</sub>R show the mushroomshaped structure consistent with early negative-stained images (81), whereas the cryo-EM structure in the presence of Ca<sup>2+</sup> shows an opened structure with disrupted subunit interactions (85), which is in line with the early negative staining studies (81, 106).

Recently, crystallization of a truncated IP<sub>3</sub>R1 including 2,217 residues (IP<sub>3</sub>R2217) was reported (112). Rod-shaped diffracting crystals of IP<sub>3</sub>R2217 and the bipyramidal crystals of a truncated IP<sub>3</sub>R1 including 1,585 residues (IP<sub>3</sub>R1585) were obtained, and X-ray crystal structures of the mouse IP<sub>3</sub>R1 cytosolic domain were determined at a resolution of 5.8 to 7.4 Å. The crystal structure of the large cytosolic domain of IP<sub>3</sub>R2217 could assign five domains: an N-terminal SD, IBC, and three curvature helical domains (HD1–3) (**Figure 2***c*). Comparison of IP<sub>3</sub>R2217 structures in the absence and presence of IP<sub>3</sub> shows conformational changes by IP<sub>3</sub> (112).

Among the various regulators, which modulate IP<sub>3</sub>-dependent channel opening by binding to discrete allosteric sites,  $Ca^{2+}$  is the most important regulator for IP<sub>3</sub>R (6, 9, 10). In 2002, the first article about  $Ca^{2+}$ -induced global structural changes in tetrameric IP<sub>3</sub>R1, revealed by negative-staining EM and limited enzymatic proteolysis, was published (106). The results were confirmed

SCA: spinocerebellar ataxia

**RyR:** ryanodine receptor

**JD-Ca<sup>2+</sup>:** juxtamembrane domain Ca<sup>2+</sup>

**CD-Ca<sup>2+</sup>:** cytoplasmic domain Ca<sup>2+</sup> by  $Ca^{2+}$ -dependent accessibility with large polyethylene glycol maleimide molecules (113). This finding was confirmed in living cells using fluorescence resonance energy transfer between two fluorescent proteins fused to the N terminus of individual subunits (114). Ca<sup>2+</sup> rigorously determines the channel activity of IP<sub>3</sub>R and a low  $Ca^{2+}$  level acts as an essential coagonist for IP<sub>3</sub>-gated  $Ca^{2+}$ release, whereas a high  $Ca^{2+}$  level inversely acts as a feedback inhibitor (9, 10). This bell-shaped regulation suggests the existence of an activation site and an inhibitory site for  $Ca^{2+}$  binding in the IP<sub>3</sub>R. Early biochemical analyses using  $Ca^{2+}$  overlay suggest various  $Ca^{2+}$ -binding sites (115). Accordingly, Ca<sup>2+</sup>-binding sites should be distributed not only in the IBC/SD or channel domains but also in the large regulatory/coupling domains. A recent cryo-EM study uncovered the molecular detail upon the global conformational changes in the tetrameric human  $IP_3R3$  (Figure 2d) (85). Notably, the cytosolic domain of  $hIP_3R3$  solved by cryo-EM in the presence of high  $Ca^{2+}$ concentrations is almost consistent with the X-ray crystal structure of mIP<sub>3</sub>R1 (112). The cryo-EM structures in the presence of  $Ca^{2+}$  reveal two  $Ca^{2+}$ -binding sites in the regulatory/coupling domains, and a high concentration of Ca<sup>2+</sup> induces the disruption of numerous interactions between subunits, which confirmed the earlier studies and clarified the  $Ca^{2+}$ -dependent inhibition mechanism at a high resolution (85). The juxtamembrane domain (JD)-Ca<sup>2+</sup>, near the residue corresponding to E2100 of IP<sub>3</sub>R1 (116), should be presumably critical for  $Ca^{2+}$ -dependent activation. By contrast, the cytoplasmic domain (CD)- $Ca^{2+}$ -binding site is located between two structural domains, an armadillo-repeat domain 2 (ARM2) and a central linker domain, suggesting that CD- $Ca^{2+}$  should stabilize the spatial relationship between these domains and that this conformational change should be a causal factor for subunit interaction. The large structural change by dissociation between subunits has never been reported in RyR, even though RyR is regulated by  $Ca^{2+}$  in a bell-shaped manner similar to  $IP_3R$ . This difference could be due to the distinct property between RyR and IP<sub>3</sub>R, and we could speculate that the intersubunit interaction in the IP<sub>3</sub>R tetramer should be weaker than that in RyR. The large-scale structural change by Ca<sup>2+</sup> could elucidate the inhibitory mechanism of high  $Ca^{2+}$  concentration, but how the low concentration of  $Ca^{2+}$  could induce conformational changes to activate the IP<sub>3</sub>-dependent channel gating remains unclear.

A recent study about IP<sub>3</sub>R in unicellular organisms demonstrated the important features of  $Ca^{2+}$ -dependent regulation. Many putative IP<sub>3</sub>R genes in unicellular organisms encode the conserved amino acid sequence at the pore, and critical amino acid residues within IP<sub>3</sub>-binding sites are also conserved in Holozoa, including *Capsaspora*, but not in fungi and earlier organisms. The most recent study of IP<sub>3</sub>R in *Capsaspora owczarzaki* demonstrated that IP<sub>3</sub>R targets the ER, binds IP<sub>3</sub>, exhibits  $Ca^{2+}$  release activity, and forms hetero-oligomers (117). Therefore, the *C. owczarzaki* gene should be a common ancestor of vertebrate IP<sub>3</sub>R is not activated by  $Ca^{2+}$  that activates vertebrate IP<sub>3</sub>R, although important residues that coordinate with JD-Ca<sup>2+</sup> (E1882, E1946, Q1949, and T2581 in hIP<sub>3</sub>R3) are all conserved. Phylogenic analyses demonstrated that IP<sub>3</sub>R genes should predate RyR genes because Bikonta cells have IP<sub>3</sub>R but not RyR genes (117). These findings suggest that the Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release function common among IP<sub>3</sub>R and RyR was acquired during the evolution between Holozoa and vertebrates.

#### ENSEMBLE OF IP<sub>3</sub>-BOUND STATES IN THE TETRAMERIC IP<sub>3</sub>R

Given the lack of cooperativity of IP<sub>3</sub>-binding events in the tetramer (79, 118), each subunit would behave independently. Therefore, the conformations of four subunits in the tetrameric channel structure is probably stochastic due to the number of bound IP<sub>3</sub> molecules. Strong evidence for stoichiometry recently showed that the tetrameric IP<sub>3</sub>R requires four IP<sub>3</sub> molecules to open the channel (119). The diverse states of IP<sub>3</sub>-bound conformations in the tetrameric IP<sub>3</sub>R were

recently revealed by three-dimensional classification using cryo-EM (Figure 2e) (85). The location of the HD2/ARM2 domain was variable in these states, and showed a 17-Å shift, consistent with the large-scale motion predicted by comparing cryo-EM structure with X-ray crystal structure (112). Importantly, global conformational changes from IP<sub>3</sub>-binding sites to near the channel domain were shown in fourfold symmetry structure, of which four IP<sub>3</sub>-binding sites were fully occupied with IP<sub>3</sub>. In these conformations, the  $\alpha$ -helical domain near IP<sub>3</sub>-binding sites moves relative to the  $\beta$ -domain ring stabilized by the HS-loop including Y167/W168. This structural change is consistent with the proposed global conformational changes from the IP<sub>3</sub>-binding site to the channel domain (112). The five states of IP<sub>3</sub>-bound IP<sub>3</sub>R suggest that the structural trajectory concerted movements upon IP3 binding; local conformational change near the IBC, coupled with movement of the large curvature helical domains that results in a 5° rotation of the JD-Ca<sup>2+</sup> site, and a 17-Å movement of HD2/ARM2, which coordinates with the CD-Ca<sup>2+</sup> at the interface with HD1/central linker domain (85). The HD2/ARM2 domain could move in each subunit because the cryo-EM data show asymmetric tetramers; the four IP3-binding sites are even occupied (Figure 2e). The possible conformational changes in  $Ca^{2+}$ -binding sites by IP<sub>3</sub> suggest that IP<sub>3</sub> binding should presumably cooperate with the JD and CD Ca<sup>2+</sup>-binding activities.

Cryo-EM also revealed the 4.1-Å structure of rat IP<sub>3</sub>R1 bound to an IP<sub>3</sub> analogue and adenophostin A, a metabolite that was discovered in *Penicillium breviocompactum* as a potent agonist of IP<sub>3</sub>R (120). This demonstrates the ligand-induced conformational changes within the IBC, which are basically consistent with the conformational changes on IP<sub>3</sub> binding (83). The presence of 100 nM of adenophostin A and 300 nM of  $Ca^{2+}$  activates IP<sub>3</sub>R channels, but no opening of a  $Ca^{2+}$  pore gate was determined in the cryo-EM. In the *apo*-state, the diameter of the selective filter was too large to select hydrated ions, but the diameter of adenophostin A-IP<sub>3</sub>R1 was narrow enough to accomplish this. In this report, the authors obtained no  $Ca^{2+}$  matching density near the site corresponding to the JD  $Ca^{2+}$ -binding site and no sufficient dilation to allow a hydrated  $Ca^{2+}$  ion to pass through (83). Therefore, the ways in which adenophostin A and  $Ca^{2+}$  can cooperate to open the  $Ca^{2+}$  channel remain unclear.

# Long-Range Allosteric Coupling from IP<sub>3</sub> to Ca<sup>2+</sup> Gates


The aforementioned structural studies demonstrated several conformations bound to IP<sub>3</sub>, Ca<sup>2+</sup>, and adenophostin A, but the structures of opened channels were never obtained. To discuss the mechanism of channel opening, we should consider not only structures but also functional data. In the past 30 years, two models for the gating mechanism were proposed: One is that the IBC and SD directly bind to the channel domain for gating (121), whereas the other is long-distance coupling from the IBC to the channel (81, 122). Recently, the latter long-distance allosteric coupling theory was supported by cryo-EM analyses, which demonstrated that the IBC/SD is located  $\sim$ 90 Å away from the Ca<sup>2+</sup> conducting gate. Cryo-EM has showed direct contacts of a C-terminal domain through a long helical bundle connecting to the sixth pore-forming transmembrane helix (84), so the authors proposed that the IBC should directly move the C-terminal helical bundles to open the channel. However, functional analyses of IP<sub>3</sub>R1 did not indicate that the IP<sub>3</sub>R function was impaired by the deletion of C-terminal residues that directly bind to the IBC in the cryo-EM structure (112, 123). Moreover, a chimera IP<sub>3</sub>R swapped with the C-terminal region of RyR, which has no homology with IP<sub>3</sub>R C-terminal domain, can release  $Ca^{2+}$  in response to IP<sub>3</sub> (92). On the basis of these functional data, contact of the IBC to C-terminal helices should not be essential for the IP<sub>3</sub>-dependent gating mechanism. Undoubtedly, the C-terminal coiled regions near the C terminus, which has no contact with the IBC/SD in the cryo-EM, should be pivotal for tetramer formation and/or domain interaction, as indicated by previous reports (123, 124).

The mutagenesis of full-length mouse  $IP_3R1$  has revealed the small structure constructed by 21 amino acid residues, referred to as the leaflet (Figure 2) (112). The leaflet directly contacts a linker domain (83); therefore, this leaflet-linker domain interacting site should be a key functional pathway of allosteric coupling from the IBC to the  $Ca^{2+}$  channel. The sequence alignment of  $IP_3R$  and RyR indicates that the equivalent leaflet region in the RyR intervenes into the Ca<sup>2+</sup>- and  $Zn^{2+}$ -binding sites in the three-dimensional structure revealed by cryo-EM (104). This finding has been confirmed by a recent study (85) suggesting integrative roles of the leaflet region underlying channel activation. Cryo-EM revealed that Ca<sup>2+</sup> coordinates with side chains of four amino acid residues in RyR, corresponding to E1977, H1979, E2041, and Q2044 residues in IP<sub>3</sub>R1. This was confirmed by a recent study in which the atomic density of JD  $Ca^{2+}$  was obtained in this binding site (85). Considering the essential role of the E2100 residue in the  $Ca^{2+}$  dependent activation (116), we can suppose that this JD  $Ca^{2+}$  binding site should be essential for channel opening by IP<sub>3</sub>. In the RyR, the  $Zn^{2+}$ -binding pocket constructed by critical residues corresponding to C2610 and C2613 residues in IP<sub>3</sub>R1 is conserved in the IP<sub>3</sub>R of all unicellular and multicellular organisms. The functional role of Zn<sup>2+</sup> ions in the IP<sub>3</sub>R remains largely unknown, but a mutagenesis study demonstrated a complete loss of IP<sub>3</sub>R function with a C2610 or C2613 mutation (79), suggesting that Zn<sup>2+</sup> may be an essential cofactor for stabilizing the structure around these residues; this is referred to as the gatekeeper domain (79). Therefore, this leaflet region linking the regulatory/ coupling and channel domains should transmit the IP<sub>3</sub>-dependent conformational changes to the  $Ca^{2+}$  channel. This idea is also supported by an X-ray crystallography study that demonstrated how IP<sub>3</sub> physically opens the  $Ca^{2+}$  channel over a long distance (112). During activation of IP<sub>3</sub>R, the movement of the leaflet region could shift the pore-forming transmembrane helix to open the  $Ca^{2+}$  pore consequently. In particular, the face of the leaflet contacting the linker domain contains highly conserved isoleucine (I2195), glutamate (E2196), and isoleucine (I2197) residues in IP<sub>3</sub>R of all isoforms, various animals, and all known unicellular organisms, including T. cruzi and T. brucei. Thus, this region is a plausible candidate for mediating the allosteric gating transmission to the channel domain.

Importantly, the IP<sub>3</sub> never opens the channel of IP<sub>3</sub>R without  $Ca^{2+}$ . Previous functional analysis indicates that a low  $Ca^{2+}$  level acts as an essential coagonist for IP<sub>3</sub>-gated  $Ca^{2+}$  release (9, 10). The requirement of dual ligands is an important basis for signaling cross talk between  $IP_3$ signaling and  $Ca^{2+}$  signaling. However, global conformational changes by IP<sub>3</sub> can be induced by  $IP_3$  only and require no  $Ca^{2+}$ , as suggested by X-ray crystallography and cryo-EM studies (81, 85). In this case, we suggest that IP<sub>3</sub> can cause global structural changes, but the channel cannot open (Figure 2f, top). By contrast,  $Ca^{2+}$  concentration is sufficient to bind to the JD  $Ca^{2+}$  binding site near the leaflet, and  $Ca^{2+}$  binding should stabilize the spatial configuration between regulatory/ coupling and channel domains to efficiently transmit a force from the IBC to the channel (Figure 2f, middle). In the presence of high  $Ca^{2+}$ , CD  $Ca^{2+}$  stabilizes the HD2/ARM2 domains and induces the large-scale structural changes associated with broken interaction between subunits (81, 85) (Figure 2f, bottom). In this structure, locally IP<sub>3</sub>-dependent conformational changes take place, but the fixed end formed at the subunit interface is broken, and the torque force from IBC should still show no transmission to the channel via the leaflet region, even though IP<sub>3</sub> is produced in the cell. The structural basis of the activation mechanism by  $Ca^{2+}$  is quite important, warranting further investigation.

# **REGULATORY MECHANISMS OF IP<sub>3</sub>R**

To understand the IP<sub>3</sub>R regulatory mechanisms, we mapped the known sites for binding proteins (**Figure** 3a), posttranslational modifications (**Figure** 3b), and mutations causing human brain



(Caption appears on following page)

#### Figure 3 (Figure appears on preceding page)

Model for IP<sub>3</sub>R plasticity. The map of the sites for binding proteins (*a*), posttranslational modifications (*b*), and mutations in genetic diseases (*c*). Amino acid numbers in panels *a* and *b* are represented in the number of mouse IP<sub>3</sub>R1 (P11881), and those in panel *c* are shown in the number of human IP<sub>3</sub>R1 isoform 2 (splicing sites SI, SII, SIII) (NP\_002213.5). (*d*-*i*) Structural plasticity in IP<sub>3</sub>R assembly. We propose structural plasticity that involves dynamic structural changes of IP<sub>3</sub>R assembly, including transformation of IP<sub>3</sub>R itself and association/dissociation of binding proteins. (*d*) P-IRBIT and IP<sub>3</sub>R form a complex and (*e*) IP<sub>3</sub> dissociates it. CA8/CARP and IP<sub>3</sub>R form a complex, but the SCA29 mutant IP<sub>3</sub>R cannot build it because the mutant cannot bind to CA8/CARP (94). (*f*) In the stacked endoplasmic reticulum (ER), IP<sub>3</sub>R makes head-to-head structures. The micrograph of negatively stained IP<sub>3</sub>R1 was obtained by electron microscopy. Each arrow indicates a particle of tetrameric IP<sub>3</sub>R. In boxes to the right, characteristic class averages of head-to-head IP<sub>3</sub>R1 are shown. (*g*) A model for transformations of IP<sub>3</sub>R. On the left is a head-to-head arrangement of tetrameric IP<sub>3</sub>R. (*b*) Ca<sup>2+</sup> waves and Ca<sup>2+</sup> oscillation (*i*) should determine structural plasticity of IP<sub>3</sub>R at each microdomain.

diseases (Figure 3c) in the IP<sub>3</sub>R1 structural model. Cytochrome c (cyt c), a mitochondrial hemoprotein involved in the electron transfer system, is released during mitochondria-dependent apoptosis and binds proximally to the leaflet region (125, 126), suggesting that cyt c should affect the leaflet-mediated gating transmission. Another important regulator, Bcl-xL (127), also binds near the leaflet region. A recent report showed that in biphasic regulation, the low concentrations of Bcl-xL activated the channel, whereas high concentrations inhibited it; furthermore, BclxL bound to two distinct sites, H1 (residues 2,571–2,606) and H4 (residues 2,690–2,732) (128). Near the leaflet region is also a target area for alternative splicing variants of the  $\alpha$  isoform of the transient receptor potential 4 (αhTRP4) channel but of the other isoform βhTRP4 channel, which associates with the C terminus of IP<sub>3</sub>R (residues 2,556–2,713 of IP<sub>3</sub>R1) (129). C2214 of rat  $IP_3R1$  is one of the three candidates for the palmitovlation site as the triple mutations (C56A/C849A/C2214A) reduced palmitovlation to 25% in wild-type IP<sub>3</sub>R1 and impaired Ca<sup>2+</sup> release by T cell receptor stimulation in Jurkat T cells (130). The palmitoyl acyl transferase enzyme interacting with Selk proteins would catalyze palmitoylation (130). The S2681 residue of IP<sub>3</sub>R1 is phosphorylated by protein kinase B, which is known as Akt kinase (Figure 3b); this phosphorylation should suppress  $Ca^{2+}$  release from IP<sub>3</sub>R because the S2681A mutant increased the  $Ca^{2+}$  release and the mitochondrial  $Ca^{2+}$  uptake and apoptosis (131), and staurosporine-induced caspase-3 activation in the S2681A mutant was more significant than in the wild-type or S2681E mutant (132). Around this site, S2684, S2685, S2687, and S2712 of mouse IP<sub>3</sub>R1 were phosphorylated as determined by mass spectrometry and shown in a database for phosphorylation (133). S2246 located near the leaflet was phosphorylated (134), and T2056, Y2640, and Y2266 of mouse  $IP_3R_1$  could be phosphorylated (133). Interestingly, these sites should be accessible for the modifying enzymes, but how they will affect IP<sub>3</sub>R function and apoptosis remains elusive. In human genetic diseases, previous reports demonstrated mutations in the  $IP_3R$  (Figure 3c), and major mutation sites are located at the IBC to impair the  $IP_3$ -binding activity, as shown recently (94). The E2046 residue is substituted to G or Q [E2094G/Q in hIP<sub>3</sub>R1 (NP\_001161744.1)] in Gillespie syndrome (135). A three-base-pair deletion at K2548 showed no IP<sub>3</sub>R function as measured in the triple knockout cells lacking IP<sub>3</sub>R1-3 (136). The mutation of F2538L [F2552L in the hIP<sub>3</sub>R1  $(NP_001093422.2)$ ] has no functional characterization, but it might impair IP<sub>3</sub>R function (136). The mutations of E2046 or its presence outside the IBC should affect allosteric gating transmission, whereas the G2491R residue [G2539R in the hIP<sub>3</sub>R1 (NP\_001161744.1)] at the  $Ca^{2+}$  pore should result in failure of  $Ca^{2+}$  permeation (135).

Among known binding partners, only P-IRBIT competitively inhibits IP<sub>3</sub> binding (**Figure 3***a*). P-IRBIT binds to the IP<sub>3</sub>-binding site via 10 critical amino acid residues that coordinate with a phosphorous group of IP<sub>3</sub> between the  $\beta$ - and  $\alpha$ -rich domains and prevents IP<sub>3</sub> from accessing the binding pocket. P-IRBIT itself has never behaved as an agonist (137); therefore, negative charges

CA8/CARP: carbonic anhydrase-related protein

of the phosphate groups in the disordered region of P-IRBIT (137) and a Long-IRBIT splicing variant (138) are probably attracted to the critical residues with positive charges but could not stabilize these conformations to open the channel, similar to a nonspecific inhibitor, heparin. The IP<sub>3</sub>-binding core is also a target for a Bcl-2-like 10 (Nrz) that is required for Ca<sup>2+</sup> signaling during epiboly and gastrulation in zebrafish (139) (Figure 3a). The Nrz protein requires E255 but not the critical amino acid residues for IP<sub>3</sub> binding and molecular docking simulation, suggesting that E255 of zebrafish IP<sub>3</sub>R1 most likely contacts Nrz C20. Because the Nrz protein inhibits the IP<sub>3</sub>-binding activity, the Nrz should affect the conformational dynamics or stability around the interface between  $\beta$ - and  $\alpha$ -rich domains in a different manner from P-IRBIT. In contrast to inhibition by P-IRBIT and Nrz, the guanine nucleotide exchange factor SWAP-70-like adaptor of T cells (SLAT) activated IP<sub>3</sub>R1 in T cells by binding to the IP<sub>3</sub>-binding domain (140). Disruption of the SLAT-IP<sub>3</sub>R1 interaction inhibited T cell receptor-stimulated Ca<sup>2+</sup> signaling, activation of the transcription factor called nuclear factor of activated T cells (NFAT), and production of cytokines, suggesting that this interaction is required for T cell activation. The critical site for SLAT binding (residues 400-417) (Figure 3a) is near the IP<sub>3</sub>-binding pocket and the interface between subunits. Thus, SLAT would facilitate the IP<sub>3</sub>-mediated conformational change and/or stabilize the subunit interface. These proteins should differentially regulate IP<sub>3</sub>R function, raising the question of how they affect dynamic changes and/or stability in the IBC by an induced fit mechanism and/or conformational selection during IP<sub>3</sub>-binding events. Homer (141) and CaM (142) also bind to the SD region (Figure 3a). Many other proteins, such as receptor of activated protein C kinase 1 (RACK1) (7), EB3 (143), AKAP9A-kinase anchor protein 9 (AKAP9) (144), Bcl-2 (145), CaM (146), carbonic anhydrase-related protein (CA8/CARP) (147), caspase-3 (148), calpain (149), and Bok (150), bind to the large regulatory/coupling domain (Figure 3a), suggesting the regulation of conformational status within this domain to control the allosteric gating. The SCA29 mutation of V1538M within the CA8/CARP-binding site of IP<sub>3</sub>R1 completely eliminated its interaction with CA8 and CA8-mediated IP<sub>3</sub>R1 inhibition. Furthermore, pathological mutations in CA8/CARP decreased CA8/CARP-mediated suppression of IP<sub>3</sub>R1 by reducing the interaction with IP<sub>3</sub>R1 (94). These results suggest the mechanisms by which pathological mutations cause aberrant assembly changes in IP<sub>3</sub>R1.

Residue S436 of IP<sub>3</sub>R1 is phosphorylated by a mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK) pathway (151, 152), which enhances the activity of IP<sub>3</sub>R1 (152). This site at the transitional zone from  $\beta$ - and  $\alpha$ -rich domains faces to the inside of tetrameric IP<sub>3</sub>R (83) (Figure 3b). Thus, this modification requires conformational changes to expose it to the surface. Around the IBC, Y353 is exposed to the surface and phosphorylated by Fyn kinase (153), T420 (154) is located in the IBC, and the SD contains a S150 phosphorylation site and presumed palmitoylation site C56. Two phosphorylation sites, S421 and T799, are phosphorylated by cyclin-dependent kinase (Cdc2/CyB), which increases the IP<sub>3</sub>-binding activity (155). S421 is close to Y353 and exposed to the top surface; T799 (equivalent to T795 in  $IP_3R3$ ) is close to the CD- $Ca^{2+}$  site (85). Phosphorylation of S150 by CaMKII, but not the S150A mutant, leads to inhibition of IP<sub>3</sub>R channel activity, and a phosphomimetic mutant S150E exhibits a constitutively low open probability (156). The S150 residue is not exposed to the surface (83, 85), suggesting that CaMKII requires conformational changes in IP<sub>3</sub>R. The S703 residue located in the regulatory/coupling domain (HD1) is phosphorylated (157). The regulatory/coupling domain is also phosphorylated at the amino acid residues equivalent to S825, S1228, S1593 (158), Y1391 (159), Y1596, and T1873 (133) in the mouse IP<sub>3</sub>R1. In addition to these phosphorylation sites, the ubiquitination (160, 161) and acetylation (162) of lysine residues were also reported in the IP<sub>3</sub>R, although the roles of major parts of these sites were uninvestigated. In cells expressing the T930A mutant, IP<sub>3</sub>R function and IP<sub>3</sub> binding affinity are activated more than the wild-type receptors, whereas cells expressing the T930E mutant oppositely show a decreased  $Ca^{2+}$  release in response to IP<sub>3</sub> uncaging (163). The  $Ca^{2+}$  content in ER is due to a modest overexpression of IP<sub>3</sub>R1 and a threefold increased phosphorylation of IP<sub>3</sub>R1 on S1716, a protein kinase A consensus site, is implicated in the ER  $Ca^{2+}$  leak (164). Glycogen synthase kinase 3 $\beta$  should modify S1756 and regulates mitochondrial  $Ca^{2+}$  transfer via IP<sub>3</sub>R at the MAM (165). These phosphorylation sites within the regulatory/coupling domain (equivalent to T945 and S1755 of mouse IP<sub>3</sub>R) are involved in important functions, but their X-ray crystal or cryo-EM structures remain unknown.

Causative mutation sites in spinocerebellar ataxia and related diseases are localized near the IP<sub>3</sub>-binding site at the interface between the  $\beta$ - and  $\alpha$ -rich domains and in the  $\alpha$ -helical domain (**Figure 3***c*), including four residues of human IP<sub>3</sub>R1: R241K (166), T267M/R (167, 168), S277I (168), and A280D (166). Human E497K (166) (equivalent to E512 of mouse IP<sub>3</sub>R1) is next to the critical residue R511 of mouse IP<sub>3</sub>R1, which coordinates with the phosphorus group of IP<sub>3</sub> (80). Human T579I (168) and N587D (169) are neighboring the helix binding with the phosphorus group of IP<sub>3</sub> (80). Human P1059L (170) (equivalent to P1049 of rat IP<sub>3</sub>R1) is located at the HD1/ARM2 of regulatory/coupling domains (83). The P1059L mutation resulted in higher IP<sub>3</sub>-binding affinity than the wild type (171), suggesting that the P1059L mutation (172) is located at the edge of HD3/ARM3 distal from the HD1/ARM2 domain, and V1538M [V1547M in hIP<sub>3</sub>R1 (NP\_00161744.1)] (169) lies at the region with unsolved structure. Interestingly, IP<sub>3</sub>R1 function was impaired by almost all SCA29 mutations but not by CA8/CARP-related S1478D and V1538M mutants (94), suggesting that the SCA29 disease should occur by two different mechanisms in the IP<sub>3</sub>R1.

# **PROPOSED IP<sub>3</sub>R PLASTICITY UNDERLYING DIVERSE FUNCTIONS**

The recent progress in cryo-EM and X-ray crystallography have strongly contributed to understanding the *apo*-state or IP<sub>3</sub>/Ca<sup>2+</sup>-bound state. Static views of these structures are important for considering the abovementioned regulation by binding partners, posttranslational modifications, and genetic mutations in IP<sub>3</sub>R. Moreover, they teach us regulation mechanisms of how binding partners control IP<sub>3</sub>R and how enzymes directly modify buried residues. To provide a framework for elucidating regulation of the IP<sub>3</sub>R in various cell types, we propose here a model for protein plasticity within IP<sub>3</sub>R (**Figure 3***d***-***i*). This concept is based on the diverse conformational changes of IP<sub>3</sub>R per se, a large number of binding proteins, and various posttranslational modifications. We also define that protein plasticity includes allosteric gating and structural changes by IP<sub>3</sub> or Ca<sup>2+</sup>, which can confer a discrete function to each IP<sub>3</sub>R assembly at each cellular microdomain. Importantly, the proposed IP<sub>3</sub>R plasticity is also supported by the fact that transglutaminase enzymatically locks the conformation to impair IP<sub>3</sub>R functions by cross-linking between subunits (173); that is, plasticity should be necessary for functions. Our proposed concept indicates that the signaling hub of IP<sub>3</sub>R itself can be transformable due to spatiotemporal signaling at microdomains for short or long periods.

Given the function of IP<sub>3</sub>R at the MAM or ER-PM, the IP<sub>3</sub>R at ER-ER contact sites should regulate certain functions, such as Ca<sup>2+</sup> transport from ER to mitochondria, or other functions, such as a scaffold of IP<sub>3</sub>R binding proteins. In the IP<sub>3</sub>R tetramer, the top surface of IP<sub>3</sub>R should be accessible so that binding proteins, including P-IRBIT, Nrz, SLAT, Homer, CaM, RACK1, EB3, and Sig-1R near the MAM, would easily access but compete for their binding sites. Binding efficiency should be due to the structure of IP<sub>3</sub>R assembly. In particular, the IP<sub>3</sub>R assembly with P-IRBIT is controlled by IP<sub>3</sub>, and local IP<sub>3</sub> signaling including production and diffusion should determine the structure of individual IP<sub>3</sub>R assembly (**Figure 3***d*). hTRP3 at the PM associates with human  $IP_3R_3$  through two sites (174), which are located in the regulatory/conduction domain, suggesting that these associations should be dependent on structural states of  $IP_3R$  assembly at PM-ER contact sites. Several phosphorylation sites, including Y353 and S150, are located at the top of  $IP_3R$  tetramers (Figure 3b), so this phosphorylation should be also affected by the status of IP<sub>3</sub>R assembly. In the case of CA8/CARP, formation of the IP<sub>3</sub>R-CA8/CARP complex is dependent on the point mutation (Figure 3e). This genetic mutation in IP<sub>3</sub>R should affect the protein plasticity of IP<sub>3</sub>R-CA8/CARP assembly and is probably critical for the cerebellar ER, where both IP<sub>3</sub>R and CA8/CARP are enriched. These structural modifications that occur through binding proteins, modifying enzymes, and generating genetic mutations should locally or temporally determine each assembly structure and result in rapid or chronic protein plasticity at cellular microdomains. Ubiquitination is also an important posttranslational modification of IP<sub>3</sub>R at the microdomains. Recent studies have clearly demonstrated that ubiquitin-regulated IP<sub>3</sub>R3 plasticity could control IP<sub>3</sub>R3 functions at the microdomain (175, 176), probably near the MAM, indicating its role in cancer cell apoptosis. The F-box protein FBXL2 binds IP<sub>3</sub>R3, and the PTEN competes with FBXL2 for IP<sub>3</sub>R3 binding. These assembly structures control proteasome-mediated degradation to limit  $Ca^{2+}$  flux from ER into mitochondria (176). BRCA1-associated protein 1 (BAP1), a potent tumor suppressor gene product, localizes at the ER and binds to deubiquitinate  $IP_3R_3$ ; consequently, BAP1 modulates Ca<sup>2+</sup> release from the ER into mitochondria to promote apoptosis (175).

IP<sub>3</sub>R assembly is formed not only by binding proteins but also by IP<sub>3</sub>R itself, according to actual images of purified IP<sub>3</sub>R visualized by early EM studies (81, 106). A view with twofold symmetry represents the first true side view of the IP<sub>3</sub>R (81) and indicates the presence of a head-to-head state of IP<sub>3</sub>R (**Figure** 3f); the head-to-head structure was sensitive to Ca<sup>2+</sup>. The dimensions of head-to-head assembly are consistent with the suggested structures at ER-ER membrane contact sites (23, 59–62). How the head-to-head assembly forms with the twofold symmetry is unknown, but we suggest that a specific mechanism should form this ordered binding interface to act at the ER-ER membrane contact sites. This large-scale protein plasticity of IP<sub>3</sub>R assembly should confer peculiar functions at the microdomain.

Early observations of purified IP<sub>3</sub>Rs also provided real images of the windmill-shaped tetramers of IP<sub>3</sub>R1 and demonstrated that relative amounts of windmill structures were dependent on Ca<sup>2+</sup> (81). A recent cryo-EM study clarified the molecular mechanism at atomic resolutions (85). The phosphorylation of S2681 located at the inner helical bundle (Figure 3b) was also enhanced by  $Ca^{2+}$  (113), suggesting that the Akt/PKB kinase could efficiently access the S2681 residue to the  $Ca^{2+}$ -bound conformations. The other protein-binding sites for cyt c, Bcl-xL, and other modification sites around the leaflet may be inaccessible for these associating proteins and modifying enzymes in the structure in the absence of  $Ca^{2+}$  (Figure 3g). The sites of functional phosphorylation by CaMKII and MAPK/ERK pathways also face to the inside of tetramer. These facts cannot be explained without large-scale structural plasticity in IP<sub>3</sub>R. The Ca<sup>2+</sup>-bound windmill state is a disadvantage for gating transmission, as the ring structure with  $\beta$ -rich domains that should serve as a fixed point during allosteric gating transmission is disrupted. However, this transformation by  $Ca^{2+}$  should be reversible (106), and thus modification or binding proteins should reversibly affect IP<sub>3</sub>R functions. In particular, the cyt c bound to IP<sub>3</sub>R should be released from mitochondria (125, 126), and Bcl proteins should localize at the surface of the mitochondrial membrane (127, 128); therefore, these associations should be mainly assembled near the MAM microdomain. Experimental data demonstrated that nonfunctional IP<sub>3</sub>R with Ca<sup>2+</sup> pore mutations (177) or with deletion of large cytosolic domains, including IP<sub>3</sub>-binding sites (177), could regulate staurosporine-induced apoptosis in chicken B cells. Therefore, the high Ca<sup>2+</sup> state with inactivated IP<sub>3</sub>-induced Ca<sup>2+</sup> release should present discrete functions in the regulation of apoptotic processes.

Our proposed IP<sub>3</sub>R plasticity can aid in adapting individual functions at each microdomain, and spatiotemporal IP<sub>3</sub> or  $Ca^{2+}$  signaling at the microdomain should dynamically regulate the incidence of IP<sub>3</sub>R plasticity. In the past 20 years, genetically encoded protein indicators were developed for monitoring spatiotemporal patterns of IP<sub>3</sub> and Ca<sup>2+</sup> concentrations in numerous cell types. Although the mechanism of these dynamics should be probably due to the cell types or stimulants (178), the spatiotemporal dynamics of IP<sub>3</sub> and  $Ca^{2+}$  concentrations play important roles in regulating diverse functions, including gene expression, synaptic plasticity, fertilization, and cell death (6, 8). Considering its intrinsic property,  $IP_3R$  plasticity should be regulated by the spatiotemporal pattern of local IP<sub>3</sub> and  $Ca^{2+}$  concentrations. Previous studies on  $Ca^{2+}$  signaling have demonstrated  $Ca^{2+}$  puffs (179) and  $Ca^{2+}$  wave phenomena (178, 180). This polarized and spatially defined Ca<sup>2+</sup> signaling could determine the cellular distribution of Ca<sup>2+</sup>-dependent plasticity in IP<sub>3</sub>R (Figure 3b), as  $Ca^{2+}$ -dependent structural changes in IP<sub>3</sub>R requires no IP<sub>3</sub> (81, 106). During  $Ca^{2+}$  oscillation evoked by IP<sub>3</sub>, IP<sub>3</sub>R should change into at least three states (Figure 3*i*). In the presence of low  $Ca^{2+}$ ,  $Ca^{2+}$  can bind to a high-affinity  $Ca^{2+}$  sensor site or a JD-Ca<sup>2+</sup> site (Figure 2a and d); IP<sub>3</sub> can also bind to IP<sub>3</sub>R, which could release Ca<sup>2+</sup>. However, once  $Ca^{2+}$  concentrations could reach sufficiently high levels to bind to low affinity sites, most likely CD-Ca<sup>2+</sup> sites, this high Ca<sup>2+</sup> relocates HD2/ARM2 domains and causes an opening of the  $\beta$ -ring structure and closure of the Ca<sup>2+</sup> channel gate by a flapping motion (106), as indicated by cryo-EM (85). Then, the concentration would be decreased by pumping back to the ER or out of cells, and the structure would transform into the resting state because the  $Ca^{2+}$ -dependent conformational changes are reversible (106). Thus, it is conceivable that temporal dynamics in  $IP_3R$  structures should occur under recurrent  $Ca^{2+}$  oscillation, and oscillatory dynamics should provide the incidence of rearrangements in IP<sub>3</sub>R assembly at local microdomains. The property of oscillatory changes of Ca<sup>2+</sup> concentration could determine biological consequences; for example,  $Ca^{2+}$  oscillation determines gene expression (181, 182), and temporal patterns of  $Ca^{2+}$  oscillation should determine cell apoptosis (183). The temporal pattern of  $Ca^{2+}$  concentrations should also determine the temporal behavior of IP<sub>3</sub>R structures that could affect the accessibility of binding proteins and modifying enzymes. Importantly, IP<sub>3</sub>R plasticity could determine not only the association of these regulatory molecules but also the dissociation of binding molecules regulated by these  $Ca^{2+}$  and/or IP<sub>3</sub> temporal patterns. In this case, the dissociated molecules could be considered presumable third messengers, such as P-IRBIT. These properties of protein plasticity within IP<sub>3</sub>R may confer an ability to regulate cellular plasticity in response to various cellular stimuli.

# CONCLUSION

In the past 40 years, from its discovery to recent research progress, numerous studies have demonstrated that IP<sub>3</sub>R mediates diverse functions at cellular microdomains, and its aberrant regulation results in a variety of human diseases. IP<sub>3</sub>R genes and IP<sub>3</sub>-mediated gating mechanisms already existed when multicellular organisms evolved from unicellular ancestors 800 million years ago, and these primitive genes have subsequently evolved into three vertebrate isoforms. In mammals, further translational variants have since evolved, and posttranslational modifications and binding proteins have added further dimensions to mammalian IP<sub>3</sub>R regulation. This increasing regulation of IP<sub>3</sub>R probably conferred plasticity to IP<sub>3</sub>R in order to adapt to diverse environments at cellular microdomains of pathophysiological states. The structures of IP<sub>3</sub>R determined by recent emerging structural analyses, including cryo-EM and X-ray crystallography, provide a new structural basis for allosteric gating to understand the core mechanism of IP<sub>3</sub>-gated Ca<sup>2+</sup> release and a new conceptual framework for protein plasticity underlying diverse functions in ligand-gated ion channels and other functional proteins. The next steps should be to observe these protein dynamics in action to decipher the regulatory mechanisms deeply. Our proposed concept of IP<sub>3</sub>R plasticity should not only explain how binding partners or enzymes can target inaccessible sites but also provide a mechanistic basis for the specific function regulated by spatiotemporal IP<sub>3</sub> and Ca<sup>2+</sup> signaling at each microdomain. To observe such protein dynamics, concrete cellular examples are needed. In particular, knowledge of protein plasticity will require high-quality assessment of protein components and posttranslational modification of protein assembly at each microdomain. In the future, empirical observations of dynamic motions in action will require new imaging technologies, and analyses of molecular behavior at the microdomains will be necessary to better understand the physiological roles of structural plasticity at discrete microdomains. We suggest that these structural plasticity mechanisms triggered by dynamic transformations of the IP<sub>3</sub>R assembly at each microdomain, including Ca<sup>2+</sup>-dependent regulation, binding proteins, and posttranslational modifications, are involved in state-dependent properties of locally diverse functions. In case of differentiated and polarized cells, we can assume that these protein mechanisms presumably control local plasticity at cellular microdomains in many bodily organs, including the brain.

# **DISCLOSURE STATEMENT**

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

# ACKNOWLEDGMENTS

K.H. was supported by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research C (15K06791) and Innovative Areas (Brain Protein Aging and Dementia Control; 17H05711). K.M. was supported by Scientific Research S (25221002) from the Japan Society for the Promotion of Science; and by ICORP/ICORP-SORST from the Japan Science and Technology Agency.

# LITERATURE CITED

- Mikoshiba K, Changeux JP. 1978. Morphological and biochemical studies on isolated molecular and granular layers from bovine cerebellum. *Brain Res.* 142:487–504
- 2. Mikoshiba K, Huchet M, Changeux JP. 1979. Biochemical and immunological studies on the P<sub>400</sub> protein, a protein characteristic of the Purkinje cell from mouse and rat cerebellum. *Dev. Neurosci.* 2:254–75
- Crepel F, Dupont JL, Gardette R. 1984. Selective absence of calcium spikes in Purkinje cells of staggerer mutant mice in cerebellar slices maintained in vitro. *J. Physiol.* 346:111–25
- Maeda N, Niinobe M, Nakahira K, Mikoshiba K. 1988. Purification and characterization of P<sub>400</sub> protein, a glycoprotein characteristic of Purkinje cell, from mouse cerebellum. *7. Neurochem.* 51:1724–30
- Furuichi T, Yoshikawa S, Miyawaki A, Wada K, Maeda N, Mikoshiba K. 1989. Primary structure and functional expression of the inositol 1,4,5-trisphosphate-binding protein P<sub>400</sub>. *Nature* 342:32–38
- Foskett JK, White C, Cheung KH, Mak DO. 2007. Inositol trisphosphate receptor Ca<sup>2+</sup> release channels. *Physiol. Rev.* 87:593–658
- Patterson RL, Boehning D, Snyder SH. 2004. Inositol 1,4,5-trisphosphate receptors as signal integrators. Annu. Rev. Biochem. 73:437–65
- Berridge MJ. 2016. The inositol trisphosphate/calcium signaling pathway in health and disease. *Physiol. Rev.* 96:1261–96

- Iino M. 1990. Biphasic Ca<sup>2+</sup> dependence of inositol 1,4,5-trisphosphate-induced Ca release in smooth muscle cells of the guinea pig taenia caeci. *J. Gen. Physiol.* 95:1103–22
- 10. Bezprozvanny I, Watras J, Ehrlich BE. 1991. Bell-shaped calcium-response curves of Ins(1,4,5)P<sub>3</sub>- and calcium-gated channels from endoplasmic reticulum of cerebellum. *Nature* 351:751–54
- Matsumoto M, Nakagawa T, Inoue T, Nagata E, Tanaka K, et al. 1996. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. *Nature* 379:168–71
- Inoue T, Kato K, Kohda K, Mikoshiba K. 1998. Type 1 inositol 1,4,5-trisphosphate receptor is required for induction of long-term depression in cerebellar Purkinje neurons. *J. Neurosci.* 18:5366–73
- Hisatsune C, Kuroda Y, Akagi T, Torashima T, Hirai H, et al. 2006. Inositol 1,4,5-trisphosphate receptor type 1 in granule cells, not in Purkinje cells, regulates the dendritic morphology of Purkinje cells through brain-derived neurotrophic factor production. *J. Neurosci.* 26:10916–24
- Hisatsune C, Miyamoto H, Hirono M, Yamaguchi N, Sugawara T, et al. 2013. IP<sub>3</sub>R1 deficiency in the cerebellum/brainstem causes basal ganglia-independent dystonia by triggering tonic Purkinje cell firings in mice. *Front. Neural Circuits* 7:156
- Sugawara T, Hisatsune C, Le TD, Hashikawa T, Hirono M, et al. 2013. Type 1 inositol trisphosphate receptor regulates cerebellar circuits by maintaining the spine morphology of purkinje cells in adult mice. *J. Neurosci.* 33:12186–96
- Sugawara T, Hisatsune C, Miyamoto H, Ogawa N, Mikoshiba K. 2017. Regulation of spinogenesis in mature Purkinje cells via mGluR/PKC-mediated phosphorylation of CaMKIIβ. PNAS 114:E5256–65
- Tsuboi D, Kuroda K, Tanaka M, Namba T, Iizuka Y, et al. 2015. Disrupted-in-schizophrenia 1 regulates transport of *ITPR1* mRNA for synaptic plasticity. *Nat. Neurosci.* 18:698–707
- Monai H, Ohkura M, Tanaka M, Oe Y, Konno A, et al. 2016. Calcium imaging reveals glial involvement in transcranial direct current stimulation-induced plasticity in mouse brain. *Nat. Commun.* 7:11100
- Nizar K, Uhlirova H, Tian P, Saisan PA, Cheng Q, et al. 2013. *In vivo* stimulus-induced vasodilation occurs without IP<sub>3</sub> receptor activation and may precede astrocytic calcium increase. *J. Neurosci.* 33:8411– 22
- Petravicz J, Fiacco TA, McCarthy KD. 2008. Loss of IP<sub>3</sub> receptor-dependent Ca<sup>2+</sup> increases in hippocampal astrocytes does not affect baseline CA1 pyramidal neuron synaptic activity. *J. Neurosci.* 28:4967–73
- Sherwood MW, Arizono M, Hisatsune C, Bannai H, Ebisui E, et al. 2017. Astrocytic IP<sub>3</sub>Rs: contribution to Ca<sup>2+</sup> signalling and hippocampal LTP. *Glia* 65:502–13
- Okubo Y, Kanemaru K, Suzuki J, Kobayashi K, Hirose K, Iino M. 2019. Inositol 1,4,5-trisphosphate receptor type 2-independent Ca<sup>2+</sup> release from the endoplasmic reticulum in astrocytes. *Glia* 67:113– 24
- Satoh T, Ross CA, Villa A, Supattapone S, Pozzan T, et al. 1990. The inositol 1,4,5,-trisphosphate receptor in cerebellar Purkinje cells: quantitative immunogold labeling reveals concentration in an ER subcompartment. *J. Cell Biol.* 111:615–24
- Pinton P, Pozzan T, Rizzuto R. 1998. The Golgi apparatus is an inositol 1,4,5-trisphosphate-sensitive Ca<sup>2+</sup> store, with functional properties distinct from those of the endoplasmic reticulum. *EMBO J*. 17:5298–308
- Gerasimenko OV, Gerasimenko JV, Tepikin AV, Petersen OH. 1995. ATP-dependent accumulation and inositol trisphosphate- or cyclic ADP-ribose-mediated release of Ca<sup>2+</sup> from the nuclear envelope. *Cell* 80:439–44
- Stehno-Bittel L, Perez-Terzic C, Clapham DE. 1995. Diffusion across the nuclear envelope inhibited by depletion of the nuclear Ca<sup>2+</sup> store. *Science* 270:1835–38
- Huh YH, Yoo SH. 2003. Presence of the inositol 1,4,5-triphosphate receptor isoforms in the nucleoplasm. FEBS Lett. 555:411–18
- Fadool DA, Ache BW. 1992. Plasma membrane inositol 1,4,5-trisphosphate-activated channels mediate signal transduction in lobster olfactory receptor neurons. *Neuron* 9:907–18
- Kuno M, Maeda N, Mikoshiba K. 1994. IP<sub>3</sub>-activated calcium-permeable channels in the inside-out patches of cultured cerebellar Purkinje cells. *Biochem. Biophys. Res. Commun.* 199:1128–35
- Echevarria W, Leite MF, Guerra MT, Zipfel WR, Nathanson MH. 2003. Regulation of calcium signals in the nucleus by a nucleoplasmic reticulum. *Nat. Cell Biol.* 5:440–46

- 31. Bading H. 2013. Nuclear calcium signalling in the regulation of brain function. *Nat. Rev. Neurosci.* 14:593-608
- Ondrias K, Lencesova L, Sirova M, Labudova M, Pastorekova S, et al. 2011. Apoptosis induced clustering of IP<sub>3</sub>R1 in nuclei of non-differentiated PC12 cells. *J. Cell Physiol.* 226:3147–55
- Ikebara JM, Takada SH, Cardoso DS, Dias NM, de Campos BC, et al. 2017. Functional role of intracellular calcium receptor inositol 1,4,5-trisphosphate type 1 in rat hippocampus after neonatal anoxia. *PLOS ONE* 12:e0169861
- Khan AA, Soloski MJ, Sharp AH, Schilling G, Sabatini DM, et al. 1996. Lymphocyte apoptosis: mediation by increased type 3 inositol 1,4,5-trisphosphate receptor. *Science* 273:503–7
- El-Daher SS, Patel Y, Siddiqua A, Hassock S, Edmunds S, et al. 2000. Distinct localization and function of <sup>1,4,5</sup>IP<sub>3</sub> receptor subtypes and the <sup>1,3,4,5</sup>IP<sub>4</sub> receptor GAP1<sup>IP4BP</sup> in highly purified human platelet membranes. *Blood* 95:3412–22
- Guillemette G, Balla T, Baukal AJ, Catt KJ. 1988. Characterization of inositol 1,4,5-trisphosphate receptors and calcium mobilization in a hepatic plasma membrane fraction. *J. Biol. Chem.* 263:4541– 48
- Vazquez G, Wedel BJ, Bird GS, Joseph SK, Putney JW. 2002. An inositol 1,4,5-trisphosphate receptordependent cation entry pathway in DT40 B lymphocytes. *EMBO J*. 21:4531–8
- Dellis O, Dedos SG, Tovey SC, Taufiq-Ur-Rahman, Dubel SJ, Taylor CW. 2006. Ca<sup>2+</sup> entry through plasma membrane IP<sub>3</sub> receptors. *Science* 313:229–33
- Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN. 2005. Acidocalcisomes—conserved from bacteria to man. Nat. Rev. Microbiol. 3:251–61
- Lander N, Chiurillo MA, Storey M, Vercesi AE, Docampo R. 2016. CRISPR/Cas9-mediated endogenous C-terminal tagging of *Trypanosoma cruzi* genes reveals the acidocalcisome localization of the inositol 1,4,5-trisphosphate receptor. *J. Biol. Chem.* 291:25505–15
- Huang G, Bartlett PJ, Thomas AP, Moreno SN, Docampo R. 2013. Acidocalcisomes of *Trypanosoma brucei* have an inositol 1,4,5-trisphosphate receptor that is required for growth and infectivity. *PNAS* 110:1887–92
- Li FJ, He CY. 2014. Acidocalcisome is required for autophagy in *Trypanosoma brucei*. Autophagy 10:1978– 88
- Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, et al. 1998. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca<sup>2+</sup> responses. *Science* 280:1763–66
- Csordas G, Renken C, Varnai P, Walter L, Weaver D, et al. 2006. Structural and functional features and significance of the physical linkage between ER and mitochondria. *J. Cell Biol.* 174:915–21
- Szabadkai G, Bianchi K, Varnai P, De Stefani D, Wieckowski MR, et al. 2006. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca<sup>2+</sup> channels. *J. Cell Biol.* 175:901–11
- Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N, Hall MN. 2013. mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. *PNAS* 110:12526–34
- Hamasaki M, Furuta N, Matsuda A, Nezu A, Yamamoto A, et al. 2013. Autophagosomes form at ERmitochondria contact sites. *Nature* 495:389–93
- Garvey M, Klose H, Fischer R, Lambertz C, Commandeur U. 2013. Cellulases for biomass degradation: comparing recombinant cellulase expression platforms. *Trends Biotechnol.* 31:581–93
- 49. Iwasawa R, Mahul-Mellier AL, Datler C, Pazarentzos E, Grimm S. 2011. Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction. *EMBO J*. 30:556–68
- Cárdenas C, Müller M, McNeal A, Lovy A, Jaňa F, et al. 2016. Selective vulnerability of cancer cells by inhibition of Ca<sup>2+</sup> transfer from endoplasmic reticulum to mitochondria. *Cell Rep.* 14:2313–24
- Bonneau B, Ando H, Kawaai K, Hirose M, Takahashi-Iwanaga H, Mikoshiba K. 2016. IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact. *eLife* 5:e19896
- Hayashi T, Su TP. 2007. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca<sup>2+</sup> signaling and cell survival. *Cell* 131:596–610

- Brailoiu E, Chakraborty S, Brailoiu GC, Zhao P, Barr JL, et al. 2019. Choline is an intracellular messenger linking extracellular stimuli to IP<sub>3</sub>-evoked Ca<sup>2+</sup> signals through sigma-1 receptors. *Cell Rep.* 26:330–37.e4
- Petkovic M, Jemaiel A, Daste F, Specht CG, Izeddin I, et al. 2014. The SNARE Sec22b has a nonfusogenic function in plasma membrane expansion. *Nat. Cell Biol.* 16:434–44
- Fernandez-Busnadiego R, Saheki Y, De Camilli P. 2015. Three-dimensional architecture of extended synaptotagmin-mediated endoplasmic reticulum-plasma membrane contact sites. PNAS 112:E2004–13
- Lur G, Sherwood MW, Ebisui E, Haynes L, Feske S, et al. 2011. InsP<sub>3</sub> receptors and Orai channels in pancreatic acinar cells: co-localization and its consequences. *Biochem. J.* 436:231–39
- Okeke E, Parker T, Dingsdale H, Concannon M, Awais M, et al. 2016. Epithelial-mesenchymal transition, IP<sub>3</sub> receptors and ER-PM junctions: translocation of Ca<sup>2+</sup> signalling complexes and regulation of migration. *Biochem. J.* 473:757–67
- 58. Wang Q, Wang Y, Downey GP, Plotnikov S, McCulloch CA. 2016. A ternary complex comprising FAK, PTPα and IP<sub>3</sub> receptor 1 functionally engages focal adhesions and the endoplasmic reticulum to mediate IL-1-induced Ca<sup>2+</sup> signalling in fibroblasts. *Biochem. J.* 473:397–410
- Otsu H, Yamamoto A, Maeda N, Mikoshiba K, Tashiro Y. 1990. Immunogold localization of inositol 1, 4, 5-trisphosphate (InsP<sub>3</sub>) receptor in mouse cerebellar Purkinje cells using three monoclonal antibodies. *Cell Struct. Funct.* 15:163–73
- Yamamoto A, Otsu H, Yoshimori T, Maeda N, Mikoshiba K, Tashiro Y. 1991. Stacks of flattened smooth endoplasmic reticulum highly enriched in inositol 1,4,5-trisphosphate (InsP<sub>3</sub>) receptor in mouse cerebellar Purkinje cells. *Cell Struct. Funct.* 16:419–32
- Rusakov DA, Podini P, Villa A, Meldolesi J. 1993. Tridimensional organization of Purkinje neuron cisternal stacks, a specialized endoplasmic-reticulum subcompartment rich in inositol 1,4,5-trisphosphate receptors. *J. Neurocytol.* 22:273–82
- Takei K, Mignery GA, Mugnaini E, Sudhof TC, De Camilli P. 1994. Inositol 1,4,5-trisphosphate receptor causes formation of ER cisternal stacks in transfected fibroblasts and in cerebellar Purkinje cells. *Neuron* 12:327–42
- Banno T, Kohno K. 1996. Conformational changes of smooth endoplasmic reticulum induced by brief anoxia in rat Purkinje cells. *J. Comp. Neurol.* 369:462–71
- Ikemoto T, Yorifuji H, Satoh T, Vizi ES. 2003. Reversibility of cisternal stack formation during hypoxic hypoxia and subsequent reoxygenation in cerebellar Purkinje cells. *Neurochem. Res.* 28:1535–42
- Varadarajan S, Bampton ET, Smalley JL, Tanaka K, Caves RE, et al. 2012. A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. *Cell Death Differ*. 19:1896–907
- 66. Varadarajan S, Tanaka K, Smalley JL, Bampton ET, Pellecchia M, et al. 2013. Endoplasmic reticulum membrane reorganization is regulated by ionic homeostasis. *PLOS ONE* 8:e56603
- Morgan AJ, Platt FM, Lloyd-Evans E, Galione A. 2011. Molecular mechanisms of endolysosomal Ca<sup>2+</sup> signalling in health and disease. *Biochem. J.* 439:349–74
- Prinz WA. 2014. Bridging the gap: membrane contact sites in signaling, metabolism, and organelle dynamics. *J. Cell Biol.* 205:759–69
- 69. Elbaz Y, Schuldiner M. 2011. Staying in touch: the molecular era of organelle contact sites. *Trends Biochem. Sci.* 36:616–23
- Mignery GA, Newton CL, Archer BT 3rd, Sudhof TC. 1990. Structure and expression of the rat inositol 1,4,5-trisphosphate receptor. *J. Biol. Chem.* 265:12679–85
- Ross CA, Danoff SK, Schell MJ, Snyder SH, Ullrich A. 1992. Three additional inositol 1,4,5trisphosphate receptors: molecular cloning and differential localization in brain and peripheral tissues. *PNAS* 89:4265–69
- Yamamoto-Hino M, Sugiyama T, Hikichi K, Mattei MG, Hasegawa K, et al. 1994. Cloning and characterization of human type 2 and type 3 inositol 1,4,5-trisphosphate receptors. *Recept. Channels* 2:9–22
- 73. Iwai M, Tateishi Y, Hattori M, Mizutani A, Nakamura T, et al. 2005. Molecular cloning of mouse type 2 and type 3 inositol 1,4,5-trisphosphate receptors and identification of a novel type 2 receptor splice variant. *J. Biol. Chem.* 280:10305–17

- Nakagawa T, Okano H, Furuichi T, Aruga J, Mikoshiba K. 1991. The subtypes of the mouse inositol 1,4,5-trisphosphate receptor are expressed in a tissue-specific and developmentally specific manner. *PNAS* 88:6244–48
- Danoff SK, Ferris CD, Donath C, Fischer GA, Munemitsu S, et al. 1991. Inositol 1,4,5-trisphosphate receptors: distinct neuronal and nonneuronal forms derived by alternative splicing differ in phosphorylation. *PNAS* 88:2951–55
- Yamada N, Makino Y, Clark RA, Pearson DW, Mattei MG, et al. 1994. Human inositol 1,4,5trisphosphate type-1 receptor, InsP<sub>3</sub>R1: structure, function, regulation of expression and chromosomal localization. *Biochem. J.* 302(Part 3):781–90
- Regan MR, Lin DD, Emerick MC, Agnew WS. 2005. The effect of higher order RNA processes on changing patterns of protein domain selection: a developmentally regulated transcriptome of type 1 inositol 1,4,5-trisphosphate receptors. *Proteins* 59:312–31
- Yoshikawa F, Morita M, Monkawa T, Michikawa T, Furuichi T, Mikoshiba K. 1996. Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor. *J. Biol. Chem.* 271:18277– 84
- Uchida K, Miyauchi H, Furuichi T, Michikawa T, Mikoshiba K. 2003. Critical regions for activation gating of the inositol 1,4,5-trisphosphate receptor. *J. Biol. Chem.* 278:16551–60
- Bosanac I, Alattia JR, Mal TK, Chan J, Talarico S, et al. 2002. Structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with its ligand. *Nature* 420:696–700
- Hamada K, Terauchi A, Mikoshiba K. 2003. Three-dimensional rearrangements within inositol 1,4,5trisphosphate receptor by calcium. *J. Biol. Chem.* 278:52881–89
- Sato C, Hamada K, Ogura T, Miyazawa A, Iwasaki K, et al. 2004. Inositol 1,4,5-trisphosphate receptor contains multiple cavities and L-shaped ligand-binding domains. *J. Mol. Biol.* 336:155–64
- Fan G, Baker MR, Wang Z, Seryshev AB, Ludtke SJ, et al. 2018. Cryo-EM reveals ligand induced allostery underlying InsP<sub>3</sub>R channel gating. *Cell Res.* 28:1158–70
- Fan G, Baker ML, Wang Z, Baker MR, Sinyagovskiy PA, et al. 2015. Gating machinery of InsP<sub>3</sub>R channels revealed by electron cryomicroscopy. *Nature* 527:336–41
- Paknejad N, Hite RK. 2018. Structural basis for the regulation of inositol trisphosphate receptors by Ca<sup>2+</sup> and IP<sub>3</sub>. *Nat. Struct. Mol. Biol.* 25:660–68
- Sudhof TC, Newton CL, Archer BT 3rd, Ushkaryov YA, Mignery GA. 1991. Structure of a novel InsP<sub>3</sub> receptor. *EMBO J*. 10:3199–206
- Ida Y, Kidera A. 2013. The conserved Arg241-Glu439 salt bridge determines flexibility of the inositol 1,4,5-trisphosphate receptor binding core in the ligand-free state. *Proteins* 81:1699–708
- Bosanac I, Yamazaki H, Matsu-Ura T, Michikawa T, Mikoshiba K, Ikura M. 2005. Crystal structure of the ligand binding suppressor domain of type 1 inositol 1,4,5-trisphosphate receptor. *Mol. Cell* 17:193– 203
- Yamazaki H, Chan J, Ikura M, Michikawa T, Mikoshiba K. 2010. Tyr-167/Trp-168 in type 1/3 inositol 1,4,5-trisphosphate receptor mediates functional coupling between ligand binding and channel opening. *J. Biol. Chem.* 285:36081–91
- Iwai M, Michikawa T, Bosanac I, Ikura M, Mikoshiba K. 2007. Molecular basis of the isoform-specific ligand-binding affinity of inositol 1,4,5-trisphosphate receptors. J. Biol. Chem. 282:12755–64
- Lin CC, Baek K, Lu Z. 2011. Apo and InsP<sub>3</sub>-bound crystal structures of the ligand-binding domain of an InsP<sub>3</sub> receptor. *Nat. Struct. Mol. Biol.* 18:1172–74
- Seo MD, Velamakanni S, Ishiyama N, Stathopulos PB, Rossi AM, et al. 2012. Structural and functional conservation of key domains in InsP<sub>3</sub> and ryanodine receptors. *Nature* 483:108–12
- Chandran A, Chee X, Prole DL, Rahman T. 2019. Exploration of inositol 1,4,5-trisphosphate (IP<sub>3</sub>) regulated dynamics of N-terminal domain of IP<sub>3</sub> receptor reveals early phase molecular events during receptor activation. *Sci. Rep.* 9:2454
- Ando H, Hirose M, Mikoshiba K. 2018. Aberrant IP<sub>3</sub> receptor activities revealed by comprehensive analysis of pathological mutations causing spinocerebellar ataxia 29. PNAS 115:12259–64
- Ladenburger EM, Korn I, Kasielke N, Wassmer T, Plattner H. 2006. An Ins(1,4,5)P<sub>3</sub> receptor in *Parame-cium* is associated with the osmoregulatory system. *J. Cell Sci.* 119:3705–17

- Hashimoto M, Enomoto M, Morales J, Kurebayashi N, Sakurai T, et al. 2013. Inositol 1,4,5trisphosphate receptor regulates replication, differentiation, infectivity and virulence of the parasitic protist *Trypanosoma cruzi*. Mol. Microbiol. 87:1133–50
- Hashimoto M, Doi M, Kurebayashi N, Furukawa K, Hirawake-Mogi H, et al. 2016. Inositol 1,4,5trisphosphate receptor determines intracellular Ca<sup>2+</sup> concentration in *Trypanosoma cruzi* throughout its life cycle. *FEBS Open Bio* 6:1178–85
- Morales-Perez CL, Noviello CM, Hibbs RE. 2016. X-ray structure of the human α4β2 nicotinic receptor. Nature 538:411–15
- Zhu S, Stein RA, Yoshioka C, Lee CH, Goehring A, et al. 2016. Mechanism of NMDA receptor inhibition and activation. *Cell* 165:704–14
- Chen L, Durr KL, Gouaux E. 2014. X-ray structures of AMPA receptor-cone snail toxin complexes illuminate activation mechanism. *Science* 345:1021–26
- 101. Miller PS, Aricescu AR. 2014. Crystal structure of a human GABAA receptor. Nature 512:270-75
- Hassaine G, Deluz C, Grasso L, Wyss R, Tol MB, et al. 2014. X-ray structure of the mouse serotonin 5-HT3 receptor. *Nature* 512:276–81
- Mansoor SE, Lu W, Oosterheert W, Shekhar M, Tajkhorshid E, Gouaux E. 2016. X-ray structures define human P2X<sub>3</sub> receptor gating cycle and antagonist action. *Nature* 538:66–71
- 104. des Georges A, Clarke OB, Zalk R, Yuan Q, Condon KJ, et al. 2016. Structural basis for gating and activation of RyR1. *Cell* 167:145–57.e17
- Chadwick CC, Saito A, Fleischer S. 1990. Isolation and characterization of the inositol trisphosphate receptor from smooth muscle. *PNAS* 87:2132–36
- Hamada K, Miyata T, Mayanagi K, Hirota J, Mikoshiba K. 2002. Two-state conformational changes in inositol 1,4,5-trisphosphate receptor regulated by calcium. *J. Biol. Chem.* 277:21115–18
- 107. da Fonseca PC, Morris SA, Nerou EP, Taylor CW, Morris EP. 2003. Domain organization of the type 1 inositol 1,4,5-trisphosphate receptor as revealed by single-particle analysis. PNAS 100:3936–41
- Jiang QX, Thrower EC, Chester DW, Ehrlich BE, Sigworth FJ. 2002. Three-dimensional structure of the type 1 inositol 1,4,5-trisphosphate receptor at 24 Å resolution. *EMBO J*. 21:3575–81
- Serysheva II, Bare DJ, Ludtke SJ, Kettlun CS, Chiu W, Mignery GA. 2003. Structure of the type 1 inositol 1,4,5-trisphosphate receptor revealed by electron cryomicroscopy. *J. Biol. Chem.* 278:21319– 22
- Henderson R, Sali A, Baker ML, Carragher B, Devkota B, et al. 2012. Outcome of the first electron microscopy validation task force meeting. *Structure* 20:205–14
- Henderson R. 2013. Avoiding the pitfalls of single particle cryo-electron microscopy: Einstein from noise. PNAS 110:18037–41
- 112. Hamada K, Miyatake H, Terauchi A, Mikoshiba K. 2017. IP<sub>3</sub>-mediated gating mechanism of the IP<sub>3</sub> receptor revealed by mutagenesis and X-ray crystallography. *PNAS* 114:4661–66
- Anyatonwu G, Khan MT, Schug ZT, da Fonseca PC, Morris EP, Joseph SK. 2010. Calcium-dependent conformational changes in inositol trisphosphate receptors. *J. Biol. Chem.* 285:25085–93
- 114. Shinohara T, Michikawa T, Enomoto M, Goto J, Iwai M, et al. 2011. Mechanistic basis of bell-shaped dependence of inositol 1,4,5-trisphosphate receptor gating on cytosolic calcium. PNAS 108:15486–91
- 115. Sienaert I, Missiaen L, De Smedt H, Parys JB, Sipma H, Casteels R. 1997. Molecular and functional evidence for multiple Ca<sup>2+</sup>-binding domains in the type 1 inositol 1,4,5-trisphosphate receptor. *J. Biol. Chem.* 272:25899–906
- 116. Miyakawa T, Mizushima A, Hirose K, Yamazawa T, Bezprozvanny I, et al. 2001. Ca<sup>2+</sup>-sensor region of IP<sub>3</sub> receptor controls intracellular Ca<sup>2+</sup> signaling. *EMBO J*. 20:1674–80
- 117. Alzayady KJ, Sebe-Pedros A, Chandrasekhar R, Wang L, Ruiz-Trillo I, Yule DI. 2015. Tracing the evolutionary history of inositol, 1,4,5-trisphosphate receptor: insights from analyses of *Capsaspora owczarzaki* Ca<sup>2+</sup> release channel orthologs. *Mol. Biol. Evol.* 32:2236–53
- Nunn DL, Taylor CW. 1990. Liver inositol, 1,4,5-trisphosphate-binding sites are the Ca<sup>2+</sup>-mobilizing receptors. *Biochem. J.* 270:227–32
- Alzayady KJ, Wang L, Chandrasekhar R, Wagner LE 2nd, Van Petegem F, Yule DI. 2016. Defining the stoichiometry of inositol 1,4,5-trisphosphate binding required to initiate Ca<sup>2+</sup> release. *Sci. Signal.* 9:ra35

- Takahashi M, Tanzawa K, Takahashi S. 1994. Adenophostins, newly discovered metabolites of *Penicillium brevicompactum*, act as potent agonists of the inositol 1,4,5-trisphosphate receptor. *J. Biol. Chem.* 269:369–72
- 121. Boehning D, Joseph SK. 2000. Direct association of ligand-binding and pore domains in homo- and heterotetrameric inositol 1,4,5-trisphosphate receptors. *EMBO J*. 19:5450–59
- 122. Hamada K, Mikoshiba K. 2012. Revisiting channel allostery: a coherent mechanism in IP<sub>3</sub> and ryanodine receptors. *Sci. Signal.* 5:pe24
- 123. Schug ZT, Joseph SK. 2006. The role of the S4-S5 linker and C-terminal tail in inositol 1,4,5-trisphosphate receptor function. *7. Biol. Chem.* 281:24431-40
- Galvan DL, Mignery GA. 2002. Carboxyl-terminal sequences critical for inositol 1,4,5-trisphosphate receptor subunit assembly. *J. Biol. Chem.* 277:48248–60
- 125. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH. 2003. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. *Nat. Cell Biol.* 5:1051–61
- Boehning D, van Rossum DB, Patterson RL, Snyder SH. 2005. A peptide inhibitor of cytochrome c/inositol 1,4,5-trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways. PNAS 102:1466–71
- 127. White C, Li C, Yang J, Petrenko NB, Madesh M, et al. 2005. The endoplasmic reticulum gateway to apoptosis by Bcl-X<sub>L</sub> modulation of the InsP<sub>3</sub>R. *Nat. Cell Biol.* 7:1021–28
- 128. Yang J, Vais H, Gu W, Foskett JK. 2016. Biphasic regulation of InsP<sub>3</sub> receptor gating by dual Ca<sup>2+</sup> release channel BH3-like domains mediates Bcl-x<sub>L</sub> control of cell viability. *PNAS* 113:E1953– 62
- Mery L, Magnino F, Schmidt K, Krause KH, Dufour JF. 2001. Alternative splice variants of hTrp4 differentially interact with the C-terminal portion of the Inositol 1,4,5-trisphosphate receptors. *FEBS Lett.* 487:377–83
- Fredericks GJ, Hoffmann FW, Rose AH, Osterheld HJ, Hess FM, et al. 2014. Stable expression and function of the inositol 1,4,5-triphosphate receptor requires palmitoylation by a DHHC6/selenoprotein K complex. *PNAS* 111:16478–83
- Szado T, Vanderheyden V, Parys JB, De Smedt H, Rietdorf K, et al. 2008. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca<sup>2+</sup> release and apoptosis. *PNAS* 105:2427–32
- Khan MT, Wagner L 2nd, Yule DI, Bhanumathy C, Joseph SK. 2006. Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. *J. Biol. Chem.* 281:3731–37
- 133. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, et al. 2012. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined posttranslational modifications in man and mouse. *Nucleic Acids Res.* 40:D261–70
- 134. Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, et al. 2014. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. *Mol. Cell. Proteom.* 13:1690–704
- McEntagart M, Williamson KA, Rainger JK, Wheeler A, Seawright A, et al. 2016. A restricted repertoire of de novo mutations in *ITPR1* cause Gillespie syndrome with evidence for dominant-negative effect. *Am. 7. Hum. Genet.* 98:981–92
- Gerber S, Alzayady KJ, Burglen L, Brémond-Gignac D, Marchesin V, et al. 2016. Recessive and dominant de novo *ITPR1* mutations cause Gillespie syndrome. Am. J. Hum. Genet. 98:971–80
- 137. Ando H, Mizutani A, Kiefer H, Tsuzurugi D, Michikawa T, Mikoshiba K. 2006. IRBIT suppresses IP<sub>3</sub> receptor activity by competing with IP<sub>3</sub> for the common binding site on the IP<sub>3</sub> receptor. *Mol. Cell* 22:795–806
- Kawaai K, Ando H, Satoh N, Yamada H, Ogawa N, et al. 2017. Splicing variation of Long-IRBIT determines the target selectivity of IRBIT family proteins. *PNAS* 114:3921–26
- 139. Bonneau B, Nougarede A, Prudent J, Popgeorgiev N, Peyrieras N, et al. 2014. The Bcl-2 homolog Nrz inhibits binding of IP<sub>3</sub> to its receptor to control calcium signaling during zebrafish epiboly. *Sci. Signal.* 7:ra14

- 140. Fos C, Becart S, Canonigo Balancio AJ, Boehning D, Altman A. 2014. Association of the EF-hand and PH domains of the guanine nucleotide exchange factor SLAT with IP<sub>3</sub> receptor 1 promotes Ca<sup>2+</sup> signaling in T cells. *Sci. Signal.* 7:ra93
- 141. Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, et al. 1998. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP<sub>3</sub> receptors. *Neuron* 21:717–26
- 142. Kang S, Kwon H, Wen H, Song Y, Frueh D, et al. 2011. Global dynamic conformational changes in the suppressor domain of IP<sub>3</sub> receptor by stepwise binding of the two lobes of calmodulin. *FASEB J*. 25:840–50
- 143. Geyer M, Huang F, Sun Y, Vogel SM, Malik AB, et al. 2015. Microtubule-associated protein EB3 regulates IP<sub>3</sub> receptor clustering and Ca<sup>2+</sup> signaling in endothelial cells. *Cell Rep.* 12:79–89
- Tu H, Tang TS, Wang Z, Bezprozvanny I. 2004. Association of type 1 inositol 1,4,5-trisphosphate receptor with AKAP9 (Yotiao) and protein kinase A. J. Biol. Chem. 279:19375–82
- 145. Ivanova H, Ritaine A, Wagner L, Luyten T, Shapovalov G, et al. 2016. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP<sub>3</sub> receptor inhibition. *Oncotarget* 7:55704–20
- 146. Yamada M, Miyawaki A, Saito K, Nakajima T, Yamamoto-Hino M, et al. 1995. The calmodulin-binding domain in the mouse type 1 inositol 1,4,5-trisphosphate receptor. *Biochem. J.* 308(Part 1):83–88
- Hirota J, Ando H, Hamada K, Mikoshiba K. 2003. Carbonic anhydrase-related protein is a novel binding protein for inositol 1,4,5-trisphosphate receptor type 1. *Biochem. J.* 372:435–41
- Hirota J, Furuichi T, Mikoshiba K. 1999. Inositol 1,4,5-trisphosphate receptor type 1 is a substrate for caspase-3 and is cleaved during apoptosis in a caspase-3-dependent manner. *J. Biol. Chem.* 274:34433– 37
- 149. Kopil CM, Vais H, Cheung KH, Siebert AP, Mak DO, et al. 2011. Calpain-cleaved type 1 inositol 1,4,5trisphosphate receptor (InsP<sub>3</sub>R1) has InsP<sub>3</sub>-independent gating and disrupts intracellular Ca<sup>2+</sup> homeostasis. *J. Biol. Chem.* 286:35998–6010
- Schulman JJ, Wright FA, Kaufmann T, Wojcikiewicz RJ. 2013. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage. *J. Biol. Chem.* 288:25340–49
- 151. Lee B, Vermassen E, Yoon SY, Vanderheyden V, Ito J, et al. 2006. Phosphorylation of IP<sub>3</sub>R1 and the regulation of [Ca<sup>2+</sup>]<sub>i</sub> responses at fertilization: a role for the MAP kinase pathway. *Development* 133:4355–65
- Zhang N, Yoon SY, Parys JB, Fissore RA. 2015. Effect of M-phase kinase phosphorylations on type 1 inositol 1,4,5-trisphosphate receptor-mediated Ca<sup>2+</sup> responses in mouse eggs. *Cell Calcium* 58:476–88
- 153. Cui J, Matkovich SJ, deSouza N, Li S, Rosemblit N, Marks AR. 2004. Regulation of the type 1 inositol 1,4,5-trisphosphate receptor by phosphorylation at tyrosine 353. *7. Biol. Chem.* 279:16311–16
- 154. Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA. 2011. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. *Sci. Signal.* 4:rs5
- Malathi K, Kohyama S, Ho M, Soghoian D, Li X, et al. 2003. Inositol 1,4,5-trisphosphate receptor (type 1) phosphorylation and modulation by Cdc2. *J. Cell. Biochem.* 90:1186–96
- Maxwell JT, Natesan S, Mignery GA. 2012. Modulation of inositol 1,4,5-trisphosphate receptor type 2 channel activity by Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII)-mediated phosphorylation. *7. Biol. Chem.* 287:39419–28
- 157. Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, et al. 2008. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. *Mol. Cell* 31:438–48
- Humphrey SJ, Yang G, Yang P, Fazakerley DJ, Stockli J, et al. 2013. Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. *Cell Metab.* 17:1009–20
- 159. Tsai CF, Wang YT, Yen HY, Tsou CC, Ku WC, et al. 2015. Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. *Nat. Commun.* 6:6622
- Sliter DA, Aguiar M, Gygi SP, Wojcikiewicz RJ. 2011. Activated inositol 1,4,5-trisphosphate receptors are modified by homogeneous Lys-48- and Lys-63-linked ubiquitin chains, but only Lys-48-linked chains are required for degradation. *J. Biol. Chem.* 286:1074–82

- Wagner SA, Beli P, Weinert BT, Scholz C, Kelstrup CD, et al. 2012. Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. *Mol. Cell. Proteom.* 11:1578–85
- 162. Lundby A, Lage K, Weinert BT, Bekker-Jensen DB, Secher A, et al. 2012. Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. *Cell Rep.* 2:419–31
- 163. Haun S, Sun L, Hubrack S, Yule D, Machaca K. 2012. Phosphorylation of the rat Ins(1,4,5)*P*<sub>3</sub> receptor at T930 within the coupling domain decreases its affinity to Ins(1,4,5)*P*<sub>3</sub>. *Channels* 6:379–84
- 164. Boutin B, Tajeddine N, Monaco G, Molgo J, Vertommen D, et al. 2015. Endoplasmic reticulum Ca<sup>2+</sup> content decrease by PKA-dependent hyperphosphorylation of type 1 IP<sub>3</sub> receptor contributes to prostate cancer cell resistance to androgen deprivation. *Cell Calcium* 57:312–20
- 165. Gomez L, Thiebaut PA, Paillard M, Ducreux S, Abrial M, et al. 2016. The SR/ER-mitochondria calcium crosstalk is regulated by GSK3β during reperfusion injury. *Cell Death Differ*. 23:313–22
- 166. Barresi S, Niceta M, Alfieri P, Brankovic V, Piccini G, et al. 2017. Mutations in the IRBIT domain of *ITPR1* are a frequent cause of autosomal dominant nonprogressive congenital ataxia. *Clin. Genet.* 91:86–91
- 167. Ohba C, Osaka H, Iai M, Yamashita S, Suzuki Y, et al. 2013. Diagnostic utility of whole exome sequencing in patients showing cerebellar and/or vermis atrophy in childhood. *Neurogenetics* 14:225–32
- 168. Sasaki M, Ohba C, Iai M, Hirabayashi S, Osaka H, et al. 2015. Sporadic infantile-onset spinocerebellar ataxia caused by missense mutations of the inositol 1,4,5-triphosphate receptor type 1 gene. J. Neurol. 262:1278–84
- 169. Huang L, Chardon JW, Carter MT, Friend KL, Dudding TE, et al. 2012. Missense mutations in *ITPR1* cause autosomal dominant congenital nonprogressive spinocerebellar ataxia. *Orphanet 7. Rare Dis.* 7:67
- Hara K, Shiga A, Nozaki H, Mitsui J, Takahashi Y, et al. 2008. Total deletion and a missense mutation of *ITPR1* in Japanese SCA15 families. *Neurology* 71:547–51
- 171. Yamazaki H, Nozaki H, Onodera O, Michikawa T, Nishizawa M, Mikoshiba K. 2011. Functional characterization of the P1059L mutation in the inositol 1,4,5-trisphosphate receptor type 1 identified in a Japanese SCA15 family. *Biochem. Biophys. Res. Commun.* 410:754–58
- 172. Schnekenberg RP, Perkins EM, Miller JW, Davies WI, D'Adamo MC, et al. 2015. *De novo* point mutations in patients diagnosed with ataxic cerebral palsy. *Brain* 138:1817–32
- 173. Hamada K, Terauchi A, Nakamura K, Higo T, Nukina N, et al. 2014. Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptors. PNAS 111:E3966–75
- 174. Boulay G, Brown DM, Qin N, Jiang M, Dietrich A, et al. 1999. Modulation of Ca<sup>2+</sup> entry by polypeptides of the inositol 1,4,5-trisphosphate receptor (IP<sub>3</sub>R) that bind transient receptor potential (TRP): evidence for roles of TRP and IP<sub>3</sub>R in store depletion-activated Ca<sup>2+</sup> entry. *PNAS* 96:14955–60
- 175. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, et al. 2017. BAP1 regulates IP<sub>3</sub>R3-mediated Ca<sup>2+</sup> flux to mitochondria suppressing cell transformation. *Nature* 546:549–53
- 176. Kuchay S, Giorgi C, Simoneschi D, Pagan J, Missiroli S, et al. 2017. PTEN counteracts FBXL2 to promote IP<sub>3</sub>R<sub>3</sub>- and Ca<sup>2+</sup>-mediated apoptosis limiting tumour growth. *Nature* 546:554–58
- 177. Khan MT, Bhanumathy CD, Schug ZT, Joseph SK. 2007. Role of inositol 1,4,5-trisphosphate receptors in apoptosis in DT40 lymphocytes. *J. Biol. Chem.* 282:32983–90
- 178. Matsu-Ura T, Shirakawa H, Suzuki KGN, Miyamoto A, Sugiura K, et al. 2019. Dual-FRET imaging of IP<sub>3</sub> and Ca<sup>2+</sup> revealed Ca<sup>2+</sup>-induced IP<sub>3</sub> production maintains long lasting Ca<sup>2+</sup> oscillations in fertilized mouse eggs. *Sci. Rep.* 9:4829
- 179. Lock JT, Alzayady KJ, Yule DI, Parker I. 2018. All three IP<sub>3</sub> receptor isoforms generate Ca<sup>2+</sup> puffs that display similar characteristics. *Sci. Signal.* 11:eaau0344
- Prole DL, Taylor CW. 2019. Structure and function of IP<sub>3</sub> receptors. *Cold Spring Harb. Perspect. Biol.* 11. https://doi.org/10.1101/cshperspect.a035063
- 181. Uhlén P, Laestadius A, Jahnukainen T, Söderblom T, Bäckhed F, et al. 2000. α-Haemolysin of uropathogenic *E. coli* induces Ca<sup>2+</sup> oscillations in renal epithelial cells. *Nature* 405:694–97
- Wang L, Wagner LE 2nd, Alzayady KJ, Yule DI. 2017. Region-specific proteolysis differentially regulates type 1 inositol 1,4,5-trisphosphate receptor activity. *J. Biol. Chem.* 292:11714–26

- 183. Miyamoto A, Miyauchi H, Kogure T, Miyawaki A, Michikawa T, Mikoshiba K. 2015. Apoptosis induction-related cytosolic calcium responses revealed by the dual FRET imaging of calcium signals and caspase-3 activation in a single cell. *Biochem. Biophys. Res. Commun.* 460:82–87
- Mikoshiba K, Okano H, Tsukada Y. 1985. P<sub>400</sub> protein characteristic to Purkinje cells and related proteins in cerebella from neuropathological mutant mice: autoradiographic study by <sup>14</sup>C-leucine and phosphorylation. *Dev. Neurosci.* 7:179–87
- Pober JS, Sessa WC. 2007. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 7:803–15
- 186. Minichiello L. 2009. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 10:850-60
- De Bock M, Wang N, Decrock E, Bol M, Gadicherla AK, et al. 2013. Endothelial calcium dynamics, connexin channels and blood-brain barrier function. *Prog. Neurobiol.* 108:1–20
- Feske S, Skolnik EY, Prakriya M. 2012. Ion channels and transporters in lymphocyte function and immunity. *Nat. Rev. Immunol.* 12:532–47